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Chapter 1 9 
1.1 General introduction 
The term osteoarthritis (OA) is used to describe a heterogeneous group of common, age 
related musculoskeletal disorders, characterized by joint pain and limitations in joint 
laxity1. The main affected tissue in OA is the cartilage covering articular bones in joints, 
however, the disease affects all compartments of these articular joints. In addition to focal 
loss of cartilage, subchondral bone, ligaments and synovium show signs of involvement in 
OA1,2. Reliable diagnosis and classification of osteoarthritis by a comprehensive set of 
radiographic criteria was facilitated in 1957 by Kellgren and Lawrence2, which were 
illustrated in the “Atlas of standard radiographs of arthritis” in 19633. To date this grading 
system is typically used by researchers for OA classification. The grading system is based 
on the decrease of articular cartilage thickness reflected by joint space narrowing and bone 
remodeling reflected by subchondral sclerosis and osteophyte formation. This score is 
implemented in an ordinal scaling system using 5 categories representing no OA signs 
(score 0) to severe OA (score 4). Radiographs are noninvasive and easily obtainable, 
however, for OA research the collection and reading of the radiographs is relatively 
expensive and time consuming as compared to collection through clinical assessment or 
identification of subjects meeting the clinical end point of OA by receiving joint 
replacements. Furthermore, research on progression of OA using radiographs is subject to 
high heterogeneity as a result of measurement methods and reading variability4,5. 
Clinically, the OA diagnosis relies largely on manifestations of the disease such as pain and 
joint deformations. Between the clinical and radiological classification of OA a fair amount 
of disease heterogeneity is illustrated by poor correlation of these measures. The relation of 
the disease to age is demonstrated by a study performed in inhabitants of a Rotterdam area 
where going from mean ages of 55 to 70 years the prevalence of radiographic signs OA was 
increasing from 80% to 95% for any of the four major joint locations knees, hips, hands and 
spine6,7. Furthermore, a study based on a random population sample of 337 nuclear families 
from the Framingham area (Massachusetts, USA) shows that at a mean age of 61.2 already 
44.1% showed signs of radiographic OA (ROA) of the knee and out of 30 sites scored the 
mean number of affected joints was 3.4 (SD 5.3). Amongst offspring of these subjects at a 
mean age 53.9 at the time of radiographic examination 21.6% was affected by ROA at 1 or 
both knees, scoring a mean number of affected joints of 1.4 (SD 2.9)8. Although the 
correlation between clinical signs and radiological signs is not strong, both features of OA 
increase with age9. The growing number of elderly in the general population will increase 
the influence of OA on worldwide public health in the future as illustrated by a prospectus 
from the Dutch institute for health (RIVM) which predicts the incidence of OA to increase 
by as much as 52% from 2007 to 204010. 
 
1.2 Healthy cartilage 
Healthy articular cartilage is characterized by sparsely divided chondrocytes in their 
extracellular matrix (ECM). The ECM is build up by several classes of highly specialized 
proteins illustrated in Figure 1. The cartilage matrix is laid down during early development 
and the major proteins present in matured articular cartilage are collagens, a class of 
fibrillar proteins. Type II collagen is the major constituent, with a lower abundance of type 
IX and XI present. Collagens form fibrillar networks that mediate the resistance to 
compressive forces and provide tensile strength. Furthermore, collagens serve as 
scaffolding for proteoglycans, the second largest class of proteins present in the ECM. 
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These polyanionic aggregates are formed by sulphated aggrecan monomers linked by 
linking proteins to hyaluronic acid. The charged acid proteins help to retain fluid within the 
matrix, thereby contributing to the ECM integrity11,12. The surface of the articular cartilage 




Figure 1. Major extracellular matrix constituents with a collagen fibril network (A), 
proteoglycans chains (B) and side chains with hyaluronic acids (C). These proteins are laid 
down during development and maintained by sparsely divided chondrocytes (D). The 
polyanionic side chains help to retain interstitial fluid in the matrix (E). 
 
During development chondrocytes arise from the mesenchymal stem cell layer in the 
growth plate. Unlike the chondrocytes in the growth plate which develop into bone, the 
chondrocytes on the joint surface side enter a state of maturational arrest during their 
development which maintains these in their differentiated phenotype throughout life under 
physiologic conditions13. The difference between the maturational states of the growth plate 
chondrocytes and articular chondrocytes is mediated though several pathways and biologic 
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conditions, in which the Wnt-signaling plays a major role14. In addition to molecular 
signaling to maintain their differentiated phenotype, biomechanical activity and hypoxia are 
essential. The fluid movement, as a result of biomechanical activity, allows nutrients to 
enter and waste products to exit the matrix in addition to the diffusion processes15. The 
ECM is not perfused by blood or lymphatic systems, ensuring the hypoxic state with 
oxygen tension as low as 1%, which is needed to maintain the chondrocytes in their 
differentiated state16. Under healthy conditions the chondrocytes have a low metabolic 
activity while maintaining the ECM17. During live, the quality of articular cartilage may 
lessen as a result of repeated stress and micro fractures to the collagen matrix, accumulation 
of advanced glycation end products and changes in the cellular expression patterns as a 
result of aging in general18,19. Although the capacity to resist high peak stresses may be less, 
aged cartilage may still fulfill its role without any compromises to the joint laxity and 
mobility as long as the glycosaminoglycans stay entrapped in the collagen network and 
osmotic potential is retained. 
 
1.3 OA cartilage 
Macroscopic features of OA cartilage include an overall decrease of cartilage volume, 
fibrillation of the surface, vascularisation, calcification and tears. The accompanying 
chondrocyte features range from increased metabolic activity, cell cluster formation, 
dedifferentiation, hypertrophy and ultimately apoptosis12,17. Although the order in which the 
changes occur may differ from case to case, in all instances OA results in an overall 
cartilage loss and is accompanied by pain and lessening of joint laxity. Frequent 
observation in early OA chondrocytes are increased metabolic activity and proliferation 
accompanied by production of matrix degrading enzymes such as matrix metalloproteinases 
(MMPs) and aggrecanases1. The enzymatic activity of these proteins breaks up the tight 
collagen network of the ECM and shortens the aggrecan side chains, jeopardizing the 
matrix integrity. The weakened matrix is less capable of retaining fluid and loses its 
elasticity, decreasing the potential to perform its shock absorbing properties. The matrix 
becomes more prone to tears and micro fractures, which in turn demands more matrix 
maintenance from the chondrocytes and allows release of hypoxia at fracture sites by the 
resulting access to the synovial fluid. Unable to respond adequately to this higher demand 
the chondrocytes proliferate, turn hypertrophic, dedifferentiate and ultimately become 
apoptotic12,13. Once initiated, this cycle may amplify itself by rounds of matrix weakening 
and a mainly catabolic or apoptotic response from the chondrocytes. A more macroscopic 
change often observed in OA cartilage is vascularisation of the matrix from the subchondral 
bone. This loosens the hypoxic state in the articular cartilage as a result of perfusion 
allowing phenotypic changes of the chondrocytes, which can initiate formation of bone, 
illustrated by the calcification of matrix surrounding vascularized areas and formation of 
osteophytes20. Bone is also implicated as an endocrine organ which may locally 
communicate with the articular chondrocytes, possibly resulting in detrimental processes in 
response to biomechanical overload or excessive local pressures21. Immunohistochemistry 
can be used to identify different OA features and the accompanied changes observed in 
matrix and chondrocytes are schematically represented in Figure 2. These features are 
summarized in a microscopic scoring system described by Mankin et al.22, which allows 
quantification of cartilage damage. 
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Figure 2. Schematically represented the synovial fluid (I), cartilage of the upper (II), middle (III) and deep (IV) 
region, a calcified area (V) and cancellous bone (VI). (A) In healthy cartilage a smooth running surface lines the 
boundary of the tissue with the synovial fluid (1). Cells are dispersed evenly over the tissue and are in a quiescent 
state (2). The proteins of the extracellular matrix, consisting mainly of collagens and glycosaminoglycans retain 
fluid and provide tensile strength (3). A tidemark separates the cartilage from the calcified area and cancellous 
bone. (B) In OA, the overall thickness of the cartilage is lost, the surface becomes irregular with fractures (1). 
Cellular features of OA include hypocellularity, clonal expansion of the chondrocytes and chondrocyte 
hypertrophy (2). The proteins of the extracellular matrix become degraded, losing their elasticity, tensile strength 
and fluid retaining properties (3). The tidemark becomes less clear and is crossed by blood vessels (4). 
 
1.4 Heritability and genetics of OA 
Family studies have shown that a relatively large heritable component exists in OA, with 
heritability estimates ranging from 40-80%, depending on phenotype and joint site 
studied23-25. Already in the 19th century OA features were recognized as hereditary and a 
1941 study reported OA as a dominant trait26. Over the years OA has shown to have a 
complex genetic background. In comparison to other common diseases OA reports a high 
familial clustering with recurrent risk ratio’s, depending on subtype studied, between 1.66 
and 8.5324,27,28. Given these data it is apparent that genes play a substantial role in OA and 
although some rare mutations cause a monogenic early onset form of OA29, the majority of 
the heritability component is caused by a multitude of genetic factors30,31. The complexity 
of the disease makes the identification of genes involved a meticulous exercise where large 
well typed cohorts with high genetic resolution are needed to yield enough power to 
elucidate the underlying genetic background32. To date several genome wide approaches, as 
well as candidate gene studies have delivered multiple genes which show reasonably 
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consistent contributions to the disease etiology. A list of recent and striking studies in the 
genetics of OA, which were at least confirmed once or show robust numbers is supplied in 
Table 1. Identification of genes involved in a trait can be done through several approaches, 
each of which has advantages and disadvantages over the others and optimal study designs 
depend entirely on the frequency and penetrance of the genetic variation underlying the 
disease (Figure 3). 
 
  
Figure 3 Genetic study designs 
 
Rare mutations with large effect sizes are best identified by model based linkage in 
extended families where a Mendelian inheritance pattern indicates a single gene to be the 
major factor in disease onset. Model free linkage studies in affected sibling pairs may be 
the next approach to detect variants with moderate effects on disease etiology for which the 
inheritance pattern appears more complex. An advantage over the association studies is the 
resistance to genetic heterogeneity and the power to identify genetic loci which may carry 
multiple independent variants which influence disease etiology. Association studies rely on 
the sharing of ancestral disease associated alleles with lower penetrance and higher allele 
frequencies amongst cases versus controls, referred to as the common disease, common 
variant theory33. Initially, candidate gene approaches were performed, where based on 
knowledge of the disease process, the choice to characterize a specific gene used little 
genotyping resources. Obviously, this only informs the researchers on a specific locus 
thereby not identifying other genetic loci putatively involved in the disease. Technological 
advances enabled researchers to type increasingly more variants, up to a point where a 
genome wide and thereby unbiased approach could be taken and a discovery approach was 
possible next to the hypothesis based approaches. In genome wide approaches we 
distinguish a linkage approach, which is based on family studies and association approaches 
which are population based, identifying cases and controls and comparing their allele 
frequencies. The genome wide approaches suffer from large numbers of spurious signals, 
increasing with the number of tests performed. To account for this, a correction for multiple 
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testing is applied, which requires the signals to reach a ‘genome wide significance’ level of 
P < 1•10-8 before being considered as putative true signals. Although combining several 
studies in collaborative efforts to accumulate larger numbers in the genome wide studies is 
generally beneficial, there is an increased chance of heterogeneity of the study population. 
Especially in the case of a heterogeneous disease such as osteoarthritis such heterogeneity 
may prevent identification of specific risk genes, cancelling out the beneficial effects of the 
large combined study sample. Further challenges in the unbiased approaches are the lack of 
incorporation of putative gene-gene and gene-environment interactions33. Once a particular 
gene is identified as involved in a disease etiology, much work is needed to understand the 
underlying mechanism. A thorough characterization of the genetic region is needed to 
identify the (true) causal variant and quantify its contribution to the disease susceptibility 
and gain understanding of the involved molecular pathways. The recently developed second 
generation sequencing techniques now allow researchers to sequence a substantial genetic 
area in large numbers of subjects at a reasonable cost, facilitating the identification of new 
variants in these areas of interest34, which is illustrated by the recent study by Johansen et 
al, who showed an accumulation of rare variants at a series of candidate genes in 
hypetriglyceridemia cases versus controls35. 
Altogether, amongst the results of genetic studies performed in OA (subtypes) two distinct 
pathways stand out especially with multiple genes implicated. The first group is formed by 
the inflammatory pathway with inflammatory signaling proteins, their modulators, 
receptors and the inflammation driven induced degrading enzymes such as matrix 
metalloproteinases (MMPs) and aggrecanases. Some consistently associating genes from 
this group are the interleukin (IL)-1 gene cluster67-69, interleukins72,77, aggrecanases37,80 and 
prostaglandin36,37,62. The second group identified consists of genes involved in the 
developmental processes of chondrogenesis and osteogenesis such as Wnt-signaling 
proteins and bone morphogenic proteins. Some of the compelling genes in this group are 
FRZB
41,49,94, which codes for an antagonist of the Wnt-signaling, GDF555 which 
coordinates formation of bone and joints, BMP237 and BMP544,45, regulators of 
chondrogenesis and articular cartilage formation respectively. Although not all genes are 
replicated in every study, the overall view is that these developmental genes play a role in 
the disease etiology. 
 
1.5 The role of inflammatory mediators in OA 
Articular chondrocytes respond to specific cytokines by either anabolic or catabolic 
activity. Pro-inflammatory signaling mediated by e.g. IL-1β has detrimental effects on 
cartilage since the resident chondrocytes respond by producing MMP’s and aggrecanases, 
effectively degrading the surrounding matrix. On the other hand, signaling by anti-
inflammatory cytokines such as IL-10 results in anabolic activity of the chondrocytes which 
will excrete new ECM components. Under normal, healthy conditions the pro- and anti-
inflammatory signals are low and balanced thereby cancelling out their respective effects95-
97. This balanced mechanism is thought to play a role in repair of small traumas to the 
cartilage, where catabolic activity in response to pro-inflammatory signaling, resulting from 
the sensed trauma, clears the damaged matrix98,99. Subsequently, the resulting lacuna in the 
matrix is filled by the newly formed collagen matrix in response to the later stage induced 
anti-inflammatory signaling12,95,100. The cytokine response is, at least in part, under genetic 
control as is illustrated by several studies showing associations of circulating levels of 
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Table 1. Recent and confirmed genetic studies for OA susceptibility loci. 
Pathway Gene Studies + Studies - OA subtypes Gene description and function 
AACT 36,37  Knee 
Alpha 1 antiproteinase, extracellular antagonist of the Wnt-
signaling pathway 
ASPN 38-41  42,43 Hip, Knee Asporin, Cartilage extracellular protein that regulates TGF-
β signaling 
BMP2 36,37  Knee 
Bone morphogenetic protein 2, involved in the 
chondrogenesis and osteogenesis in development 
BMP5 44,45  Knee 
Bone morphogenetic protein 5, regulator of articular 
chondrocyte development 
CILP 36,37,46  Hip, LDD 
Cartilage intermediate layer protein, inhibits  
TGF-β1-mediated induction of cartilage matrix genes 
DIO2 47  Hip, GOA 




al.(in press)   
Deiodinase 3, intercellular deactivator of thyroid hormone 
in target tissues 
FRZB 41,48-51 52 
Hip/Knee, 
GOA 
Secreted frizzled related protein 3, Wnt antagonist and 
modulator of chondrocyte maturation 
GDF5 53-55  Hip 
Growth and differentiation factor 5, member of the bone 
morphogenic family, regulator of growth and 
differentiation across several tissues including bone and 
cartilage 
IGF1 43,56  Hip 
The protein is similar to insulin in function and structure 
and is a member of family of proteins involved in 
mediating growth and development.  
LRP5 57 52 Knee 
Low density lipoprotein receptor-related protein 5, receptor 
involved in the Wnt signaling via the canonical beta-
catenin pathway 
RHOB 58 59 Hip, Knee 
Ras homologue gene family member B, GTPase in tumor 
supression and antagonist in the PI3K/Akt pathway 
Developmental 
WISP1 60  Spine 
Wnt inducible signaling protein 1, target of the Wnt 
pathway regulated by beta catenin 
COX2 (PTGS2) 36,37,61,62  Knee, Spine 
Prostaglandin, modulates cartilage proteoglycan 
degradation through PGE2 
HLA 63-66  
Hand/Hip/Kee, 
GOA 
Human leukocyte antigen system, determinant of antigen 
specificity of the immune response 
IL1 cluster 43,67-70 43,69,71 Hip/Knee 
Interleukin 1 alpha, beta and receptor antagonist, regulates 
metalloproteinase gene expression in chondrocytes and 
synovium 
IL10 72,73  Knee/Hand 
Interleukin 10, anti inflammatory cytokine inhibiting IL1 
synthesis 
IL4R 74 43 Hip 
Interleukin 4 receptor, Putative role in chondrocyte 
response to mechanical signals 
Inflammatory and 
Immunity 
IL6 75-77 43 Hip/Knee 
Interleukin 6, proinflammatory cytokine, involved in 
cartilage degradation and IL1Ra induction 
Chr7q22 78  OA subtypes 
Several genes in LD block currently under investigation for 
further specification of underlying gene(s). 
ADAM12 31,37,79 42 Knee 
A Disintegrin and metalloproteinase 12, involved in 
osteoclast formation and cell-cell fusion 
ADAMTS14 80   
A disintegrin and metalloproteinase with thrombospondin 
motifs 14 
CALM1 81 41,82 Hip 
Calmodulin 1, intracellular protein interacting with 
proteins involved in signal transduction 
COL2A1 41,83-85 43 Knee Type II collagen, major constituent of articular cartilage 
COMP 41  Knee 
Cartilage oligomeric protein, cartilage matrix 
macromolecule 
EDG2 86  Knee 
Lysophosphatidic receptor encoding, EDG receptors 
mediate diverse biologic functions, including proliferation 
and chemotaxis. 
ESR1 36,87,88 43 Knee, GOA 
Estrogen receptor alpha, chondrocytic modulator of 
proteoglycan degradation and MMP mRNA expression 
LRCH1 89 90 Hip/Knee 
Leucine rich repeats and calpain homology, protein of 
unknown function 
MATN3 91,92  Hand, Spine Matrillin 3, extracellular matrix protein 
OPG 36,37  Knee Osteoprotegerin, regulator of osteogenesis 
TNA 36,37  Knee 
Tetranectin, plasminogen-binding protein involved in the 
degradation of ECM 
TXNDC3 58 59 Knee 




VDR1 36,41,59 43,93 Knee 
Vitamin D receptor, mediates vitamin D signaling which 
serum levels affect incidence and progression of OA 
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inflammatory mediators to genetic variation at genes involved in their regulation101-103. 
Cytokines are derived from several cell types, however, one of the main sources of 
cytokines are the circulating blood lymphocytes. The estimated innate capacity of 
lymphocytes to produce cytokines has been shown to associate to a range of diseases104,105 
including OA susceptibility and OA progression in sibling pairs affected by OA at multiple 
joint sites (Genetics of osteoARthritis Progression, or GARP study106). In this study, Riyazi 
et al. showed that a high innate IL-1β and low innate IL-10 (together indicating a pro-
inflammatory profile) predisposes to OA107. Furthermore, data on progression of a subset of 
these individuals over a 2 year period showed a specific innate tumor necrosis 
factor(TNF)α and IL-10 profile confers to an increased risk of knee OA progression108. The 
genetic component in variation of the LPS induced innate cytokine response is substantial, 
underlined by the high heritability of these levels ranging from 57% to 86%109. Genetic 
configuration of innate immunity might confer susceptibility to OA through a lifelong 
exposure to specific (pro-inflammatory) cytokine profiles107, as is also observed for several 
other diseases110,111. Polymorphisms in the cytokine genes were shown to explain only a 
small part of the total heritability estimate of innate immune profiles indicating 
involvement of additional loci73,109. The role of polymorphisms at the IL-1 gene cluster in 
the innate levels or OA phenotypes were studied in several smaller cohorts and to date no 
study combined the polymorphisms, innate levels and OA data in one single study. In 
addition, the ratio between IL-1β and its biological competitor IL-1 receptor antagonist 
(Ra) was suggested to be a more suitable representation of the bio-availability of IL-1β 
signal112. The low contribution of the known genetic variation at the respective cytokine 
genes to the genetic component of innate immunity indicates additional regulating 
mechanisms are involved. Identification of new loci involved in the regulation of innate 
immunity may provide new candidate genes to be tested for association to OA. In addition 
to innate immunity, synovial levels of inflammatory cytokines were reported to be elevated 
in OA joints97,113-115, whereas baseline levels of C-reactive protein (CRP) were shown to be 
associated to erosive hand OA116. Furthermore, in vitro explants and cell culture 
experiments show that the chondrocytes are a source of matrix degrading enzymes upon 
incubation with pro-inflammatory cytokines117-120. Taken together the described studies 
show that inflammatory mediators play a role in OA etiology, although for most reported 
studies it remains unclear whether the immune system signaling is merely a marker of the 
ongoing disease process, or whether this may underlie part of the etiology of the disease. 
Studies into genetics of the immune system may help elucidating cause and effect. As was 
shown in Table 1, in addition to the genetic component in OA that may be ascribed to 
genetic variation in inflammatory mediators, recent genome wide linkage and association 
scans also indicated a substantial role for genes which play a role during early development 
of the articular joints. 
 
1.6 The role of developmental characteristics in OA 
The role of skeletal development in OA was first illustrated by the onset of OA as a result 
of severe chondrodysplasia or defects in skeletal morphogenesis121,122. The joint shape is 
determined early in life, where severe malformations ultimately lead to OA. The 
endochondral ossification process plays a key role in determining joint shape during 
development and is responsible for the growth and shape of the long bones, including the 
articular joints14. In this process chondrocytes arising from a mesenchymal stem cell layer 
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subsequently proliferate, differentiate and turn hypertrophic. During these phases 
respectively, the chondrocytes increase in number, lay down a cartilage matrix and 
eventually start excreting cartilage degrading enzymes, and ultimately the initial cartilage 
layer is replaced by bone by blood vessel invasion and settlement of osteoblasts. The 
chondrocyte phases are tightly controlled by distinct gene expression patterns in which the 
Wnt-signaling is intimately involved123. Contrary to the chondrocytes in the growth plate, 
the chondrocytes of the articular layers on the long bones escape this sequence and enter a 
state of maturational arrest maintaining their differentiated phenotype. It can be 
hypothesized that less pronounced joint shape variations can predispose to OA as a result of 
a lifelong slightly altered mechanical loading of the joint. Several studies are ongoing in an 
attempt to define joint shape by the use of radiographs or MRI and relating this to the 
incidence of OA. Although confirmation is needed, initial studies show joint shape 
modeling may be used to predict OA onset or progression124,125. Through a genome wide 
linkage scan in the GARP study, a new OA susceptibility locus was identified at 
14q32.1147. Subsequent association analysis identified the local thyroid hormone regulator 
DIO2 coding for type II deiodinase (D2), which is also active in the growth plate during 
development as the most likely gene in the linkage region involved in OA etiology. Genetic 
variation at DIO2 was confirmed to associate to OA in multiple other studies across 
different geographic areas and ethnicities. DIO2 is the first gene identified which indicated 
that thyroid signaling may be involved in OA and secondly that such signaling in the 
growth plate during endochondral ossification may be involved in OA etiology126. Several 
other genetic studies likewise identified genes in the osteogenesis and chondrogenesis 
pathways that associate to OA41,55, indicating a broader involvement of genes which 
orchestrate the process of endochondral ossification. In addition to developmental 
differences originating from developmental stages these genes may contribute to OA 
etiology later in life; the processes observed in the articular chondrocytes and ECM 
resemble processes observed in the growth plate in osteogenesis95,127, possibly the (aging) 
articular chondrocytes lose their maturational arrested phenotype. Loss of this arrest allows 
articular chondrocytes to re-enter the cycle of their counterparts in the growth plate, thereby 
mimicking the downstream events and ultimately turning apoptotic and causing the 
cartilage integrity to fail. We have discussed the features of ageing and the role of 
developmental genes in OA in a review on this subject126. 
 
1.7 Outline of the thesis 
In the current thesis one of the main study populations that is being investigated is the 
GARP study, consisting of middle aged sibling pairs (total N=382) affected with OA at 
multiple joint sites. This study is characterized for OA features at four joint sites; OA at the 
hips, knees and hand and degeneration of spinal discs were assessed by radiographs as well 
as by clinical assessment106. A high level of familial clustering of these features was 
observed in the GARP study, which led us to identify the genes underlying this high 
heritable component in OA. In addition to radiological and clinical data for these joint sites, 
extensive demographic questionnaires, blood samples and urine were collected at different 
time points (0, 6, 12, 24 and 60 months). The collection of multiple time points allows 
studies aimed at identifying markers which can either show or predict OA progression. 
Genetic studies in the GARP study by Min at al. have thus far shown associations to FRZB 
and MATN3 for hand and hip OA respectively51,91. The associations of the described genes 
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in the GARP study together with the results of genetic studies in other OA cohorts explain 
only part of the heritability of OA, indicating that additional genes are involved in OA 
etiology.  
In this thesis we set off to gain more insight in the role of inflammatory mediators and their 
genetic variation in OA. The question to be answered is whether (innate) cytokine profiles 
are merely a reflection of ongoing OA processes and genetic configuration, or whether the 
genetic configuration of genes orchestrating these cytokines plays a role in OA etiology. 
We characterized several genes and inflammatory markers and investigated their respective 
roles in OA in order to elucidate whether the observed associations follow Mendelian 
randomization128, or whether an etiologic relation exists between genetics of cytokine 
regulating genes and OA. Chapter 2 describes the research performed in the GARP study to 
substantiate the causal role of inflammatory mediators and inflammation modulating genes 
in OA.  
In Chapter 2.1 we studied the interaction between genetic variation at the IL-1 gene cluster 
(IL1A, IL1B and IL1RN gene) and innate ex vivo production upon LPS stimulation of the 
IL-1β and IL-1Ra (together expressing the IL-1β bio-availability) as well as the interaction 
of these characteristics with OA. Although genetic variations associated to innate cytokine 
levels were found as described Chapter in 2.1 of this thesis and in literature, together these 
genes explain only a small part of the heritability of these levels and elucidation of 
quantitative trait loci for innate immunity might reveal new insights in the regulation of the 
cytokine response. Follow up on these putative innate modulating genes may provide more 
insights in the role of innate immunity in OA etiology. Chapter 2.2 describes a genome 
wide linkage study where we set off to identify new quantitative trait loci for innate IL-1β, 
IL-1Ra, IL-10 and TNFα and whether these associate to OA. In Chapter 2.3 we explored 
the association between CRP haplotypes and serum high sensitive CRP levels as shown by 
Carlson et al.102 and used these haplotypes and CRP levels in an association analysis with 
OA subtypes. Finally in Chapter 2.4 we investigated whether serum CRP and plasma 
cytokine and/or chemokines levels marked the ongoing OA disease process in the GARP 
study. Furthermore, using these levels we investigated whether the previously identified 
association between genetic variation at the SELS gene and pro-inflammatory cytokines101 
in plasma could also be identified in the inflammatory profiles of GARP subjects and their 
OA subtypes. 
As indicated, previous studies identified the DIO2 gene as the most likely gene explaining a 
significant linkage peak in OA sibling pairs of the GARP study47. A hypothesis on the role 
of genes involved in endochondral ossification was generated during the research of this 
thesis126. We characterized a DIO2 risk allele tagged by polymorphism rs225014 for 
possible cis regulatory elements through analyses of putative differential allelic expression 
and we sought further evidence for the involvement of D2 in OA by characterization of OA 
and non-OA cartilage for the presence of D2 including other thyroid hormone regulatory 
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Abstract 
 
Objective: To assess whether genetic variation in the interleukin (IL)-1 gene cluster 
contributes to familial osteoarthritis (OA) by influencing the innate ex vivo IL-1ß or IL-1Ra 
cytokine production. 
Methods: Innate ex vivo IL-1β and IL-1Ra production upon LPS stimulation (10 ng/ml) of 
whole blood cells was measured in the GARP study which consists of sibling pairs 
predominantly with symptomatic OA at multiple sites. Radiographic characteristics of OA 
(ROA) were assessed by Kellgren and Lawrence score. Subjects of GARP and controls of 
the Rotterdam study were genotyped for 7 single nucleotide polymorphisms (SNPs) 
encompassing the IL-1 gene cluster on chromosome 2q13. Linkage disequilibrium (LD) 
analysis, genotype and haplotype association analysis were performed in order to assess the 
relationship between the IL-1 gene cluster SNPs, innate ex vivo cytokine production and 
OA. 
Results: Haplotype VNTR, +8006 and +11100 2-2-1 of the IL1RN gene was within the 
GARP study significantly associated to lower innate ex vivo bio-availability of IL-1ß upon 
LPS stimulation (P-value = 0.026) and to subjects with ROA at the highest number of joint 
locations.  
Conclusion: We show that genetic variation at the IL-1 gene cluster associates to lower 
IL1ß bio-availability and to OA at a large number of joint locations. Furthermore, our data 
also indicates that among subjects with OA at the highest number of joints the innate 




Osteoarthritis (OA) is a common joint disease and is an important cause of pain and 
disability in the general population. Genetic factors play an important role in the etiology of 
(various subtypes) of OA1-5. There has been a large interest in the role of cytokines as 
mediators of joint damage and inflammation in the pathogenesis of OA. Chondrocytes are 
known to respond to interleukin (IL)–1β by decreasing synthesis of matrix components and 
increasing the synthesis of metalloproteinases (MMPs)6. MMPs degrade extracellular 
matrix (ECM) components in articular cartilage. IL-1Ra is the natural competitive inhibitor 
of IL1ß, occupying the cell surface IL-1 receptor without triggering signal transduction and 
its levels might be considered critical in determining the IL-1β bioavailability6. 
One way of investigating the influence of cytokine profiles on disease is by measuring 
innate ex vivo cytokine production upon lipopolysaccharide (LPS) stimulation of whole 
blood samples. Studies of twins have shown that ex vivo production of cytokines IL-1β, IL-
1Ra, TNFα, IL-10 varies by 60-70% based on heritability alone7. Subjects can thus be 
characterized as high (pro-inflammatory) or low (anti-inflammatory) producers based on 
these cytokines profiles8,9. Such a characteristic may influence susceptibility to diseases 
with an inflammatory component10-12. Data supporting this hypothesis in OA comes from 
our previous studies13 in which we demonstrated that a pro-inflammatory profile, high 
innate ex vivo cytokine IL-1β and IL-1Ra and low IL-10, occurs among subjects with 
familial OA at multiple sites of the GARP study as compared to controls. The innate ex vivo 
production of TNFα which did not associate to the onset of OA, was the only cytokine that 
predisposed to knee OA progression14. In recent years the concept that inflammation in OA 
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contributes to symptoms and augments many pathological changes has become generally 
accepted15,16, however, it is unclear whether this is a causal association or marks the 
ongoing disease process. Furthermore, the interplay between secreted IL-1ß and IL1-Ra 
levels should be taken into account since together they influence the IL-1ß bio-
availability17. 
The genes encoding IL-1α, IL-1β and IL-1Ra (IL1A, IL1B and IL1RN, respectively) reside 
within a 430 kb region on chromosome 2q13. Although not always consistently and 
determined in relative small studies, it has been shown that several DNA variants within the 
genes of the IL-1 gene cluster may be responsible for the variation in the heritable innate ex 
vivo cytokine production upon LPS stimulation12. Furthermore, in vitro experiments have 
shown functional ability of IL1B promoter SNPs to enhance IL-1ß production upon LPS 
stimulation18. The role of the IL1RN VNTR allele 2 appears most consistent in affecting of 
cytokine production in vivo19 and may be considered most important for the fine tuning of 
the IL-1ß bio-availability as determined by the ratio of the innate ex vivo cytokine 
production upon LPS stimulation of IL-1ß and IL-1Ra17. Multiple genetic association 
studies, tried to investigate whether these potential functional aspects of the IL-1 gene 
cluster polymorphisms may in part explain genetic susceptibility of OA. Previously, we and 
others have reported associations of the IL-1 gene cluster for knee, hip and hand OA20-25, 
although others failed to confirm these associations26,27. Together the effects of the IL-1 
gene cluster SNPs on innate ex vivo cytokine production and OA may be complex and 
involve interactions among different polymorphic sites and should therefore be investigated 
by means of independent haplotypes.  
Combining ex vivo IL-1ß bio-availability measures upon LPS stimulation, genetic variation 
at the IL-1 gene cluster and OA disease status in a single study population allows to assess 
possible underlying relationships28. We have tested for the influence and interaction of the 
IL-1 gene cluster polymorphisms and haplotypes on the IL-1ß bio-availability in a 
relatively large number of individuals of the GARP study. In the same study it was 
investigated whether the haplotypes relevant for IL-1ß bio-availability correlate to a 
proportioned score of the number of ROA affected joint locations.  
 
Patients and methods 
 
The GARP study (Genetics, osteoARthritis and Progression) 
The ongoing GARP study, which consists of 191 Caucasian sibling pairs of Dutch ancestry 
affected with symptomatic OA at multiple sites. Probands (aged 40-70 year) and their 
siblings were included in the GARP study with OA at multiple joint sites of the hand 
according to the American College of Rheumatology criteria or with symptomatic OA in 
two or more of the following joint sites: hand, spine (cervical or lumbar), knee or hip29. In 
the spine, knee or hip symptomatic OA was defined as having symptoms of OA in addition 
to radiographic signs30-33. 
Conventional radiographs of the hands (dorso-volar), knees (Posterior-Anterior in weight 
bearing / semi flexed and lateral), hips (AP), lumbar (AP and lateral) and cervical spine 
(AP, lateral and transoral) were obtained of all participants. This was performed in a 
standard manner with a fixed film-focus distance and a fixed joint position. Radiographic 
characteristics of OA were defined according to Kellgren and Lawrence34 by a single, 
experienced and trained radiographer according to an agreed protocol as described in detail 
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elsewhere29. In the current paper we used (the highest quartile of) the total ROA score. The 
total ROA score (0-10) represents a summed score proportional to radiological cartilage 
abnormalities at each joint location in knee (0-2), hip (0-2), hand (0-2), facet joints (0-2), 
and spinal discus degeneration DD (0-2) as described previously in detail35. The highest 
quartile of the total ROA score represents GARP subjects with the highest number of joint 
locations with radiographic abnormalities which were compared to other subjects of the 
GARP study and/or random subjects of the Rotterdam study. We compared affected sibling 
pairs from the GARP study to a random sample of unrelated subjects aged 55-65 years (n = 
809) of the Rotterdam study as reference group representing the general population36. Both 
studies comprise of Caucasian subjects from the western areas of the Netherlands with a 
mean age of 60.3 years and may represent the same genetic background. In this sample 
symptomatic OA has not been assessed. 
 
Whole-blood stimulation system  
Whole-blood sample stimulation was performed as previously described37. In short, blood 
samples were collected in pyrogen-free heparinized tubes (Endotube®, Chromogenix, 
Mölndal, Sweden). Eight-millilitre whole-blood samples were diluted 1:1 with RPMI 1640 
(Gibco Life Technologies, Paisely, United Kingdom) and stimulated with 10 ng/mL 
Escheria coli LPS (Difco Laboratories, Detroit, Mich). To minimize the influence of 
circadian rhythms and measurement errors, blood samples were taken between 8 AM and 
11 AM, the time frame between blood collection and stimulation was less than one hour 
and a half, and all stimuli were performed with the same endotoxin batch. One medium-
diluted blood without LPS was used as negative control. After 24-hour incubation, samples 
were centrifuged twice (600g) and the supernatants stored at -70ºC. IL-1β and IL-1Ra 
production were measured in one batch by enzyme-linked immunosorbent assays (ELISA) 
according to manufacturer's guidelines (Central Laboratory of the Blood Transfusion 
Service, Amsterdam, the Netherlands). Nine patients were excluded from the analyses 
because either whole-blood samples had not been obtained (N = 5) or levels of IL-1Ra or 
IL-1β were missing (N=4). 
  
Genotyping measurements 
Genomic DNA was isolated from blood samples from the GARP study, for 1 subject DNA 
was missing. In total 809 subjects of Rotterdam and 381 subjects of the GARP study were 
genotyped for 7 SNPs encompassing the IL-1 gene cluster on chromosome 2q13; 1 SNP 
located in the IL1A gene (C-889T rs1800587), 3 SNPs in the IL1B gene C3953T 
(rs1143634), T-31C (rs1143627) and C–511T (rs16944) and 3 SNPs in the IL1RN gene 
VNTR in intron 2, T8006C (rs419598) and T+11100C (rs315952). The genotypes of the 
C3953T C–511T and VNTR in the Rotterdam study were assessed previously22. The 
genotypes of the SNP were determined by mass spectrometry (homogeneous Mass ARRAY 
system; Sequenom Inc., San Diego, CA), using standard conditions. Genotypes were 
analyzed by using Genotyper 3.0 software (Sequenom Inc.). Throughout the paper the 
common alleles of the SNPs are designated 1 and the rare alleles as 2. For the controls 
genotypes from the Rotterdam study were available of 788 subjects.  
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Statistical analysis 
The contribution of the individual genotypes of the SNPs of the IL-1 gene cluster to the 
innate ex vivo cytokine production upon LPS stimulation was estimated using a mixed 
model regression analyses performed with the logarithmically transformed cytokine levels 
as dependent variable and as co-variable the genotypes of the SNPs and sex. In the mixed 
model analyses, random effects modeled the familial dependencies that might occur for the 
cytokine levels. These analyses were carried out with SPSS version 14 software (SPSS, 
Chicago, Illinois, USA). Haplotypic effects on the quantitative innate ex vivo cytokine 
production and/or total ROA scores were assessed by the THESIAS 3.1 program38 and 
adjusted for sex and/or BMI where indicated. When interpreting the THESIAS results it 
should be taken into account that in these analysis siblings of the GARP study were used as 
independent individuals. To assess the strength (odds ratio) of the haplotypic effect in the 
GARP subjects with the highest number of joints logistic regression with robust standard 
errors to adjust for family relationship39 was used in Stata SE8 software (Stata Corporation, 
USA). In this case the haplotypes of individuals were estimated by the expectation 
maximization algorithm implemented in SNPHAP version 1.3 and posterior haplotype 
probabilities were used as sampling weight in the analysis. Instead of adjusting P values a 
priori for multiple testing, nominal P values are provided in order to allow the reader to 




In Table 1 the characteristics of the 382 patients with symptomatic OA at multiple sites 
who were included in the GARP study are provided. The study consists predominantly of 
women (82%). Whole blood innate ex vivo productions of IL-1β and IL-1Ra upon LPS 
stimulation were previously measured in all subjects of the GARP study13. As the IL-1ß and 
IL-1Ra levels were significantly lower in females as compared to males (P-value = 1.6 x 
10-5 and P-value = 0.002, respectively) and the IL-1Ra levels were significantly associated 
to body mass index (BMI, P-value = 0.01), all analyses concerning these levels were 
adjusted for sex and BMI. We could not detect an effect of age to these levels. To take into 
account the interaction between IL-1ß and IL-1Ra levels, we examined the effect of the IL-
1ß bio-availability as expressed by the ratio between ex-vivo IL-1ß and IL-1Ra production 
upon stimulation with LPS. In total 7 SNPs encompassing the IL-1 cluster on chromosome 
2q13 were measured in both the GARP study and controls. All SNPs were in Hardy 
Weinberg equilibrium. In Figure 1, the linkage disequilibrium (LD) pattern of the SNPs in 
the case and control group together across the region is visualized by the HAPLOVIEW 
program of the Hapmap project40. Notably a low LD occurs between the -511 IL1B and 
VNTR IL1RN SNPs with D' = 0.41 and r2 = 0.1 dividing the region in two separate blocks, 
the first block consisting of IL1A –889, and IL1B +3953, -31, and –511 and the second 
block consisting of IL1RN gene VNTR, +8006 and +11100 which were used for the 
haplotype association analysis. 
 
Association analysis of IL-1 cluster haplotypes and IL-1ß bio-availability based on ex 
vivo production levels 
As shown in Table 2 there were 2 haplotypes in the second block (VNTR, +8006 and 
+11100) covering the IL1RN gene that associated significantly to the cytokine production 
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levels. Haplotype 2-2-1 (frequency 0.22) was associated to lower IL-1β production levels 
(P = 0.002) whereas haplotype 2-2-2 (frequency 0.02) to higher IL-1Ra production level (P 
= 1.1x10-4). 
 
Table 1: Characteristics of study populations 
 GARP study 
Total number of subjects1 382 
Number of females (%) 311 (82) 
ROA scores (> 0) of subjects within (N=382):  
Hip (%) 107 (28) 
Knee (%) 150 (39) 
Hand (%) 213 (56) 
Facet (%) 235 (62) 
DD (%) 256 (67) 
Mean total ROA score (range) 3.45 (0-9) 
Mean age in years (range) 60.3 (43-79) 
Mean body mass index in kg/m2 (SD) 27.0 (4.7) 
Mean IL1-ß /IL-1Ra ratio, IL1ß bio-availability (SE) 0.798 (0.003) 
1Numbers represent GARP subjects with symptomatic OA at multiple joint locations 
including subjects with uni and/or bilateral joint replacement (N=38 for hip and N = 8 for 
knee). DD = spinal disc degeneration SD = standard deviation IQR = interquartile range. 
 
These haplotypes are not tagged by one of the individual SNPs and the associations appear 
more significant but are in agreement with the results obtained for the genotype analysis 
(Supplementary Table 1).  
To take into account the interaction between IL-1ß and IL-1Ra levels we examined the 
effect of the haplotypes to the bio-availability as expressed by the ratio between IL-1ß and 
IL-1Ra (Table 2). As can be seen only IL1RN haplotype VNTR, +8006 and +11100 2-2-1 
showed significant lower bio-availability of IL-1ß upon LPS stimulation (P-value = 0.026). 
Next we assessed whether these haplotypes also contributed to the degree of cartilage 
abnormalities in the GARP subjects expressed by the summed ROA score of all joint 
locations. 
 
Association analysis of IL-1 cluster haplotype and OA 
For haplotype IL1RN VNTR, +8006 and +11100 2-2-1 of the second block, which 
associated significantly and consistently to lower IL-1ß availability, we could not detect an 
association among GARP subjects as compared to random controls of the Rotterdam study. 
However, when we explored the quantitative association with the total ROA score for all 
joint locations among subjects of the GARP study in THESIAS, a trend towards a higher 
mean summed ROA score was observed for haplotype 2-2-1 (P = 0.07) as compared to the 
other haplotypes. Upon further investigation it was shown that subjects that reside within 
the highest quartile of the total ROA score (ROA score > 5, N = 64) showed significant 
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association with this IL1RN haplotype with an OR of 1.76, 95%CI 1.14-2.76, P-value = 
0.011 when compared to the subjects of the Rotterdam study (N = 788) and an OR of 1.91, 
95% CI 1.21-3.02, P-value = 0.006 when compared to the remaining GARP subjects (N = 
317). Adjusting for age, sex or BMI did not considerably affect this haplotypic association. 
None of the other haplotypes was associated to OA (subtypes). 
 
 
Figure 1. Pairwise linkage disequilibrium across the IL-1 
cluster single nucleotide polymorphisms (SNPs) as 
visualized by the Haploview program and expressed by the 
linkage disequilibrium coefficient D’. 
 
When combining the effect of haplotype IL1RN VNTR, +8006 and +11100 2-2-1 to both 
IL-1ß availability and the total ROA score within GARP subjects, the haplotype was 
independently and significantly associated to lower IL-1ß availability (P-value = 0.007) and 
to subjects (25%) with highest number of joint locations with ROA (P-value = 0.006). In 
contrast, we did not observe lower innate ex vivo IL-1ß availability among the subjects with 




It was investigated whether genetic variation at the IL-1 cluster contributes to innate ex vivo 
cytokine production upon LPS stimulation and whether the relevant haplotypes contribute 
to symptomatic OA at multiple joint sites as assessed in the GARP study. 
Haplotype 2-2-1 (frequency 0.22) of the IL1RN block showed significant lower bio-
availability calculated by the ratio of IL-1ß and IL-1Ra as compared to the other IL1RN  
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Table 2. Haplotype association analysis of block 1 consisting of the IL1A (–889) and IL1B (3953, -31, and -511) 
gene and block 2 consisting of 3 the IL1RN gene;VNTR_T8006C_T11100C with the innate ex vivo IL-1β and IL-
1Ra production upon LPS stimulation of whole blood cells. 




Log IL-1β1 Log IL-1Ra Log IL-1ß / IL-1Ra 
1-1-1-1 40 1.72 (1.69-1.75) 2.14 (2.08-2.20) 0.39 (0.36-0.41) 
1-1-2-2 27 1.73 (1.69-1.77) 2.12 (2.07-2.17) 0.40 (0.37-0.42) 
2-2-1-1 22 1.77 (1.72-1.81) 2.14 (2.09-2.20) 0.40 (0.37-0.43) 
2-1-2-2 4 1.66 (1.57-1.75) 2.17 (2.08-2.26) 0.38 (0.35-0.41) 
2-1-1-1 4 1.71 (1.61-1.81) 2.11 (1.99-2.22) 0.38 (0.35-0.42) 
others 3    




Log IL-1β Log IL-1Ra Log IL-1ß / IL-1Ra 
1-1-1 44 1.75 (1.72-1.78) 2.14 (2.09-2.19) 0.40 (0.37-0.42) 
1-1-2 31 1.74 (1.71-1.78) 2.14 (2.09-2.19) 0.39 (0.36-0.42) 
2-2-1 22 1.66 (1.62-1.71)** 2.11 (2.06-2.16) 0.38 (0.35-0.40)* 
2-2-2 2 1.83 (1.58-2.08) 2.27 (2.19-2.34)*** 0.40 (0.35-0.46) 
others 1    
Data was analyzed using the THESIAS program for quantitative phenotypes for IL1β and IL1Ra levels 
logarithmically transformed. P-value is determined by comparing the specific haplotypic mean as compared to 
the haplotypic mean of all other haplotypes. 1Values for IL1ß were adjusted for sex whereas values for IL1Ra 
and IL1ß/IL1Ra were adjusted for sex and BMI. HAP = haplotype allele frequency. *P<0.05, **P<0.005 and 
***P<0.0002 
 
haplotypes (P-value = 0.026) and to subjects (25%) with highest number of joint locations 
with ROA (P-value = 0.006). Our result of this IL1RN haplotype with IL-1ß bio-availability 
are in line with the results of Vamvakopoulos et al.17 who showed that the IL1RN VNTR 
allele 2 was significantly associated to lower IL-1β production levels upon stimulation with 
LPS. Together our results confirm that genetic variation within the IL1RN gene exert their 
influence on the IL-1β bio-availability possibly via a functional difference of the IL-1Ra 
protein. As antagonist of IL-1β to the IL-1 receptor, aberrant IL-1Ra may hamper a correct 
regulation of the biological IL-1β level. In normal cartilage lower IL-1ß bio-availability, as 
result of genetic variation at the IL-1 gene cluster, may cause an inefficient repair of 
damaged cartilage and thereby influence the propensity to develop OA at various joint sites.  
To this end the association with the IL1RN VNTR, +8006 and +11100 haplotype 2-2-1 to 
lower IL-1ß availability and to ROA at the highest number of joint locations in our dataset 
appear consistent. The subsequent absence of low IL-1ß availability among this severe 
ROA subtype is, however, more difficult (final sentence of the result section). Moreover, 
we previously showed higher IL-1ß, IL-1Ra and lower IL-10 cytokine production levels 
upon LPS stimulation occur among subjects of the GARP study as compared to controls13 
whereas these levels did not predispose to knee OA progression14. A possible explanation 
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could be that the actual whole blood ex vivo cytokine production measurement is not 
entirely independent on disease status, but brings about increased sensitivity to LPS 
activation in subjects with severe OA disease pathology. In our own dataset, this 
explanation is substantiated by the observation that although the IL1RN 2-2-1 haplotype is 
more frequent among subjects with OA at the highest number of joints, the association of 
the haplotype with low IL-1ß availability gets lost in this particular group (results not 
shown) possibly due to an activated innate immune system. Similar to the relation between 
plasma CRP and ischemic events as discussed by others41, the association observed in 
epidemiological studies between high innate ex vivo cytokine IL-1ß and IL-1Ra with OA13 
may not reflect causality but rather a marker of the ongoing disease process that affects an 
individual’s sensitivity for LPS stimulation. As elegantly outlined in a review of Scanzello 
et al.
42 OA may indeed be considered as a chronic wound in which the innate immune 
response (via up regulation of Toll like receptors) may be activated by molecular signals of 
tissue damage. The fact that we observe such an effect mainly in subjects with a high 
number of OA affected joints may indicate that this is particularly true in subjects with 
advanced disease. To validate these effects further it should be investigated whether indeed 
an individuals cytokine production capacity upon LPS stimulation changes in the course of 
OA onset or progression and/or whether healthy subjects with a specific inflammatory 
cytokine production profile are prone to develop OA (at multiple joint locations). 
Our data show a common IL1RN haplotype that is significantly associated to lower IL-1ß 
availability and to subjects with highest number of joint locations with ROA. The fact that 
this association is counter intuitive to the concept that inflammation in OA contributes to 
symptoms and augments many pathological changes underlines the complex interplay 
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Supplementary Table 1. Genotype association analysis of 
logarithmically transformed innate ex vivo cytokine production upon 
LPS stimulation measured in the GARP study. 
Log IL-1β Log IL-1Ra 
Genotypes (N) 
Mean P-value1 Mean P-value1 
Overall (368 ) 3.49  4.37  
IL1A_-889 0 (172) 
IL1A_-889 1 (147) 








IL1B_3953 0 (203) 
IL1B_3953 1 (144) 








IL1B_-31 0 (160) 
IL1B_-31 1 (169) 








IL1B_-511 0 (162) 
IL1B_-511 1 (154) 








IL1RN_VNT 0 (205) 
IL1RN_VNT 1 (137) 









IL1RN_8006 0 (201) 
IL1RN_8006 1 (127) 










IL1RN_11100 1 (161) 








1Data was analyzed using mixed model regression analyses with IL1β, and IL1Ra levels logarithmically transformed as dependent 
variable and as co-variables the genotypes coded as 0, 1, 2 carriers of the rare allele and for IL1ß adjusted for sex and for IL1Ra 
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Abstract 
 
Cytokines are major immune system regulators. Previously, innate cytokine profiles 
determined by LPS stimulation were shown to be highly heritable. To identify regulating 
genes in innate immunity we analyzed data from a genome wide linkage scan using 
microsatellites in osteoarthritis patients (The GARP study) and their innate cytokine data on 
IL-1β, IL-1Ra, IL-10 and TNFα. A confirmation cohort consisted of the Leiden 85-Plus 
study. 
In this study, a linkage analysis was followed by manual selection of candidate genes in 
linkage regions showing LOD scores over 2.5. A SNP gene tagging method was applied to 
select SNPs on the basis of highest level of gene tagging and possible functional effects. 
QTDT was used to identify the SNPs associated to innate cytokine production. Initial 
association signals were modelled by a linear mixed model. Through these analyses we 
identified 10 putative genes involved in the regulation of TNFα. SNP rs6679497 in gene 
CD53 showed significant association to TNFα levels (P = 0.001). No association of this 
SNP was observed to osteoarthritis. A novel gene involved in the innate immune response 
of TNFα is identified. Genetic variation in this gene may play a role in diseases and 




The immune system is a complex network of interacting pathways and signaling proteins 
which enables organisms to respond to pathogens as well as to many other events that 
challenge homeostasis. The immune system is regulated through cytokines, which are 
mainly secreted by lymphocytes. The ability of lymphocytes to produce cytokines can be 
characterized by ex vivo stimulation with, for example, the bacterial surface molecule 
lipopolysaccharide (LPS). This ligand triggers ex vivo lymphocytes to produce a maximal 
pro-inflammatory cytokine response, subsequently followed by an anti-inflammatory 
response1. The as such determined maximal cytokine production profile has been shown to 
be stable2 and to contain a significant heritable component estimated between 53% and 
86%, indicating a strong genetic control3. 
Based on innate ex vivo cytokine profiles, individuals can be characterized as pro- or anti-
inflammatory and it has been shown that these profiles can be predisposing to diseases with 
an inflammatory component such as multiple sclerosis and cardiovascular events4,5. In 
osteoarthritis (OA), a pro-inflammatory profile may affect the articular cartilage 
homeostasis, which depends on a delicate balance of catabolic respectively anabolic 
activity induced by pro- (tumor necrosis factor (TNF)α, interleukin(IL)-1ß) and anti-
inflammatory (IL-10 and IL-1 receptor antagonist(Ra)) cytokines6,7. In line with this 
hypothesis, Riyazi et al. showed that patients of the Genetics osteoARthritis and 
Progression (GARP) study with OA at multiple joints sites simultaneously, have high 
innate IL-1β and IL-1Ra and low innate IL-10 production as compared to controls8. 
Although a later study indicated that the mechanism underlying this association may be 
more complex, it confirmed the association of genetic variation associated to the innate 
cytokine levels to OA features9. We and others have shown that genetic variation of genes 
involved in the regulation of the immune system may be reflected by a specific profile of 
circulating plasma inflammatory markers10-12. Furthermore, it was shown that DNA variants 
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within the IL10 gene and genes of the IL-1 cluster may be responsible for a part of the 
variation in the heritable innate ex vivo cytokine production upon LPS stimulation13-16. A 
large part of the heritability however, cannot be explained by the currently known genes.  
Characterisation of the genes that explain a considerable part of the individual variation in 
the innate cytokine profiles may shed more light on the regulatory elements designed to 
obtain or maintain proper balance of these cytokines. Through a better understanding of 
these elements more insight in underlying disease processes in diseases with an 
inflammatory component such as OA can be obtained, thereby enabling identification of 
putative therapeutic targets. In the present study we set off to discover such putative 
quantitative trait loci for innate cytokine levels by use of the available genome wide linkage 
data of subjects of the GARP study17, as well as data on their ex vivo LPS stimulated 
production of IL-1β, IL-1Ra, IL-10 and TNFα8. Confirmation by association analysis of 
innate cytokine levels was performed using 563 unrelated individuals of the Leiden 85-Plus 
study18. Identified genetic variation influencing the innate immunity profile was tested for 
association to OA and radiographic OA subtypes as assessed in the GARP study. 
 
Materials & methods 
 
Study subjects 
The GARP study consists of 191 Caucasian sibling pairs affected predominantly by 
symptomatic OA at multiple joint sites. Characteristics of the GARP study are listed in 
Table 1. Details on description of the phenotype and data collection are described by Riyazi 
et al.
19. As a confirmation cohort, we used the Leiden 85-Plus study which consists of 
inhabitants of Leiden (Netherlands), who were asked to participate in this study upon 
reaching the age of 85 years between September 1, 1997 and September 1, 1999. The 
response rate was 87% and in total 599 individuals were included in this study. OA data are 
not available for the Leiden 85-Plus study20. 
 
Phenotyping 
In the GARP study and Leiden 85-Plus study, for most participants (N=370 and N=563 
respectively) an ex vivo whole blood sample was stimulated with 10 ngml-1 LPS and after a 
4 hours incubation the sample was centrifuged and the TNFα levels were determined in the 
supernatant by use of an enzyme linked immunosorbent assay. In a second sample a similar 
protocol was performed with a 24 hour incubation after which the plasma levels of IL-1β, 
IL-1Ra and IL-10 were determined1,19. In concordance with previous studies3,4,5, the ex vivo 
LPS stimulated cytokine levels were not normally distributed and influenced by gender. In 
our analyses log transformed cytokine levels were used and analyses were adjusted for sex. 
 
Genotyping 
Previously, a genome wide microsatellite scan was performed in the GARP study to 
identify new OA susceptibility loci, a detailed description of the genotyping methods and 
control policy has been described by Meulenbelt et al.17. In short, 417 microsatellite 
markers on an average spacing of 10 cM across the genome were measured. Initial linkage 
peaks were identified and two peaks were fine mapped by typing 3 additional microsatellite 
markers for each in the region of linkage (Supplementary Table 1). SNP multiplex 
genotyping assays were designed using Assay Designer software 3.1. iPlex assays were 
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measured on the Sequenom MassARRAY system (Sequenom, San Diego, CA). PCR’s 
were carried out in a final volume of 5 µl and contained standard reagents and 5 ng of dried 
genomic DNA. Genotypes were called using the Genotyper v3.1 software (Sequenom, San 
Diego, CA). All SNPs were checked for deviations from Hardy-Weinberg equilibrium and 
approximately 8% of the subjects were genotyped twice as a check for genotyping and 
calling consistency. Of the 47 genotyped SNPs in this study, 3 SNPs failed quality check 
due to low amplification, bad cluster separation or low confidence in called genotypes and 
were excluded from further analysis. 
 
Linkage analysis and candidate gene selection 
The GARP microsatellite genotype data and log transformed LPS stimulated levels were 
analyzed using the variance components option implemented in Merlin to assess linkage of 
the levels to genetic loci21. Merlin output files were modified to tab delimited files with 
LOD score per marker to facilitate uploading to a custom track in the UCSC genome 
browser genome graph function. The significance level of linkage peaks was assessed by 
use of random gene dropping simulations in Merlin using 5000 reruns. The regions 
showing LOD scores over 2.5 were explored for candidate genes by use of the UCSC 
genome browser22, where the individual markers’ LOD scores were uploaded on a custom 
track. All UCSC annotated genes in the 1-LOD-drop region within the flanking areas of a 
linkage peak over 2.5 were considered for possible involvement in the cytokine response. 
This manual selection of genes was based on location within the linkage region, GO terms 
and Swissprot description provided in the UCSC genome graph function. Genes selected 
were genes which are described as being involved in immune system communication, 
antigen recognition and immune response. We selected 10 positional candidate genes (three 
linkage areas). Candidate genes were subsequently tagged using SNPs selected from the 
International HapMap Project genome browser23. SNP selection was based on genetic 
position and function as well as potential to tag genetic variation present within these genes. 
Tagger software implemented in the Haploview program with settings “r2 > 0.8” and “pair 
wise tagging” was used to optimize tagging SNP selection24. In the selection process we 
included only SNPs with minor allele frequencies over 0.05 in CEPH data. A prioritization 
was applied to SNPs in coding regions by forced inclusion of non-synonymous SNPs and 
lowest priority given to downstream SNPs. In total, 47 SNPs were selected for genotyping. 
 
Association analysis of quantitative innate cytokine levels 
The GARP data were analyzed for association of LPS levels to SNPs in the candidate genes 
using QTDT25. Initially, the -WEGA and –WEGD commands were applied to test for 
association given linkage on a specific locus under an additive and dominant model 
respectively. To test for possible population stratification we used the –AP –WEGA or –AP 
-WEGD command. Furthermore, a linear mixed model was used to model the association 
with the SNP in the GARP and Leiden 85-Plus data including sex, age, BMI as covariates. 
Here, the random family effect models correlation between siblings of the GARP study due 
to shared genetic and environmental effects26. In the combined GARP and Leiden 85-Plus 
analysis, in addition to family numbers and covariates sex, age and BMI, we included study 
identifiers in the model to correct for putative batch differences. Genotypes were coded as 0 
(homozygote common allele), 1 (heterozygote) and 2 (homozygote rare allele) to test an 
additive model and 0, 1 and 1 respectively for testing a dominant model with one degree of 
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freedom. All reported p-values are nominal p-values uncorrected for multiple testing for the 
reader’s interpretation of the results, unless mentioned otherwise. 
 
Qualitative association analysis of OA status and SNPs 
To asses association of SNPs to OA at multiple joint sites as defined in the GARP study, a 
logistic regression was performed in STATA/SE 8.0, using the Leiden 85-Plus sample as a 
reference sample, whereby we used family numbers in the GARP study as a random effect 
variable to model familial dependencies. Dominant effects for the rare allele were tested by 





The characteristics of GARP and the study sample of the Leiden 85-Plus study where both 
innate cytokine production levels and genotypes were available are shown in Table 1. The 
participants of the Leiden 85-Plus study were significantly older as compared to the GARP 
participants (P < 0.01) and we observed significant differences in the transformed LPS 
stimulated levels between the GARP and Leiden 85-Plus participants for IL-1β (P = 0.034), 
IL-1Ra (P <0.01) and TNFα (P <0.01). To check for age dependencies of the LPS 
stimulated cytokine profiles the correlation with age was analyzed. We observed no 
significant correlations of age and IL-1β, Il-10 or IL-1Ra. However, TNFα showed a 
significant (P=0.037) correlation with age with a Pearson correlation coefficient of 0.11 
(data not shown). The older subjects of the GARP study had on average a higher LPS 
stimulated TNFα level. 
 
Table 1. Characteristics GARP and Leiden 85-Plus study 
 N  The GARP Study  N Leiden 85-Plus Study 
No. - 382  - 563 
Age, mean ± SD* - 60.4 ± 7.6  - 851  
No. women (frequency)* - 301 (0.81)  - 375 (0.67) 
Mean Log(IL1β) ± SD* (variance) 370 3.49 ± 0.30 (0.088)  559 3.54 ± 0.38 (0.142) 
Mean Log(IL1Ra) ± SD* (variance) 369 4.37 ± 0.15 (0.023)  560 4.55 ± 0.20 (0.041) 
Mean Log(IL10) ± SD (variance) 369 2.87 ± 0.19 (0.035)  560 2.85 ± 0.30 (0.090) 
Mean Log(TNFα) ± SD* (variance) 368 3.87 ± 0.18 (0.032)  561 3.98 ± 0.21 (0.045) 
* Significant difference between studies (t-test) 1All subjects of the Leiden 85-Plus study were 85 years old at sampling. 
 
IL-1β, IL-1Ra and IL-10 linkage and association analysis 
The genome wide linkage analysis to find quantitative trait loci involved in innate IL-1β, 
IL-1Ra and IL-10 analyses using variance components did not reveal any evidence for 
linkage above a LOD score of 2.5 (Figure 1A, 1B and 1C respectively). We did not select 
candidate genes and single nucleotide polymorphism(SNP)s for follow up analysis of these 
traits. No substantial evidence for linkage was observed at the loci encoding cytokines IL-
1β and IL-1Ra (2q13), IL-10 (1q32.1) or TNFα (6p21.33) (Figure 1 A-D). 
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Figure 1. LOD scores for genome wide linkage analyses for QTL’s of (A) IL-1β, (B) IL-1Ra, (C) IL-10 and 
(D) TNFα. 
 
TNFα linkage and association analysis 
Genome wide linkage analysis of innate TNFα levels revealed three regions with positive 
evidence for linkage with LOD scores over a LOD score of over 2.5 (Figure 1D), of which 
1 peak reached a genome wide linkage significance level. The linkage peak on chromosome 
11q12.1 (Figure 1D, peak 2) was fine mapped using three microsatellite markers and after 
fine mapping showed a maximum LOD score of 2.57 (marker D11S1314 P = 3.0•10-4, 
genome wide p-value 0.497) between markers D11S935 and D11S901 (width 53 
megabases (Mb), Figure 2A). Furthermore on chromosome 17p13.2 (Figure 1D, peak 3) we 
observed a narrow linkage peak with maximum a LOD score of 3.38 (marker D17S938 P = 
4.0•10-5, genome wide p-value 0.064) between markers D17S831 and D17S799 (width 
5Mb, Figure 2B) which was not fine mapped. The largest peak on chromosome 1p13.3 
(Figure 1D, peak 1) was fine mapped using three additional microsatellite markers and after 
fine mapping showed a maximum LOD score of 3.77 (marker D1S2726 P = 3.0•10-4, 
genome wide p-value 0.018) between markers D1S2868 and D1S484 (width 52Mb, Figure 
2C). Within these linkage peaks we selected 10 candidate genes (Table 2). On chromosome 
11 we selected candidate genes MADD, SELH, CD6 and CD5, on chromosome 17 GPS2, 
TNFA-SF12/13 and CD68 and on chromosome 1 CSF1, CD53 and FAM19A3. The genes 
were tagged using 44 haplotype tagging SNPs, thereby tagging from 30-100% of the 
genotypic variation recorded in the HapMap database (Table 2). QTDT analysis indicated 
significant associations to TNFα levels for SNPs in CD53 and FAM19A3 (Table 2). We 
were unable to model the observed associations of FAM19A3 in a linear mixed model, 
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however, when a dominant linear mixed model was fitted for CD53 rs6679497 we again 
observed a significant association in both the GARP and Leiden 85-Plus separately (P = 
0.013 and 0.032 respectively, Table 3). When we combined the data of both studies in a 
linear mixed model using a dominant model we observed a highly significant association of 
rs6679497 (P=0.001, Table 3). The association remains significant after a Bonferroni 
correction to account for the 11 SNPs tested on the locus (corrected p-value = 0.012), or 
accounting for all 44 SNPs selected upon the linkage analysis (corrected p-value = 0.047). 
The minor allele of this intron SNP (frequency 0.48) associated with significantly lower 
innate TNFα levels. 
 
 
Figure 2. Detailed view of initial and fine mapped 
linkage peaks identified on chromosome 11 (Pane A, 
peak 2), chromosome 17 (Pane B, peak 3) and 
chromosome 1 (Pane C, peak 1). Schematically 
represented are the tested genes positions in the linkage 
area. The dotted lines represent the initial linkage signal, 
whereas the solid lines represent the finemapped linkage 
signal. 
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Table 2. Genes and selected SNPs in Linkage Peak, TNFα 
Chr Gene 
(coverage1) 





rs915357 Intron   
rs333968 Intron 0.055+ 0.060+ 
rs333970 Intron   




factors are cytokines that act in 
hematopoiesis by controlling the production, 
differentiation, and function of 2 related 
white cell populations of the blood, the 
granulocytes and the monocytes-
macrophages     
rs10494122 Intron   
rs10857833 Intron   
rs6679497 Intron 0.012* 0.009** 
rs4839581 Intron   
rs3790722 Intron   
CD53 
(52%) 
cell surface glycoprotein that is known to 
complex with integrins.. Familial deficiency 
of this gene has been linked to an 
immunodeficiency associated with recurrent 
infectious diseases caused by bacteria, fungi 
and viruses. Alternative splicing results in 
multiple transcript variants encoding the 
same protein     
rs4450019 Intron 0.019* 0.033* 




Contains conserved cysteine residues at 
fixed positions, and are distantly related to 
MIP-1alpha, a member of the CC-
chemokine family.     
rs7114704 Intron   
rs10501320 Intron   
rs10501321 Intron   
rs10838689 Intron   
rs2290149 Intron   
rs11039183 Intron   
MADD 
(68%) 
Tumor necrosis factor alpha (TNF-alpha) is 
a signaling molecule that interacts with one 
of two receptors on cells targeted for 
apoptosis. The protein encoded by this gene 
is a death domain-containing adaptor protein 
that interacts with the death domain of TNF-
alpha receptor 1 to activate mitogen-
activated protein kinase (MAPK) and 
propagate the apoptotic signal 
rs753993 Intron   
rs9420 Intron bound.   SELH 
(100%) 
This gene encodes a selenoprotein, which 
contains a selenocysteine (Sec) residue at its 
active site. rs3017889 Downstream   
rs2905504 Intron   
rs11230550 Intron   
rs11230553 Intron   
rs2283263 Intron   
rs11230559 Intron   
rs11230563 Coding exon*   
rs2074225 Coding exon*   
CD6 
(30%) 
CD6 is a monomeric 105- or 130-kD 
membrane glycoprotein that is involved in 
T-cell activation. 
rs1050922 Coding exon   
rs3862667 Intron   
rs572350 Intron   
rs671444 Intron   




Human T-cell surface glycoprotein of 
relative molecular mass (Mr) 67,000, has 
been implicated in the proliferative response 
of activated T cells and in T-cell helper 
function. 
rs637186 Coding exon*   
rs2270981 Coding Exon   GPS2 
(100%) 
This gene encodes a protein involved in G 
protein-mitogen-activated protein kinase 
(MAPK) signaling cascades. rs2292064 Coding Exon   
rs9899183 Intron   
rs12937543 Promoter   
rs4968211 Promoter   
rs11552708 Coding Exon*   
rs3803800 Coding Exon*   
rs6608 3’UTR   
TNFA-SF 
(80%) 
This gene encodes a member of the tumor 
necrosis factor superfamily. It encodes a 
hybrid protein composed of the cytoplasmic 
and transmembrane domains of family 
member 12 fused to the C-terminal domain 
of family member 13. The hybrid protein is 
membrane anchored and presents the 
receptor-binding domain of family member 
13 at the cell surface. It stimulates cycling in 
T- and B-lymphoma cell lines.     
rs9896688 Intron bound.   
rs9901673 Coding Exon*   




This gene encodes a 110-kD transmembrane 
glycoprotein that is highly expressed by 
human monocytes and tissue 
macrophagesThe protein is also a member 
of the scavenger receptor family. Scavenger 
receptors typically function to clear cellular 
debris, promote phagocytosis, and mediate 
the recruitment and activation of 
macrophages. Alternative splicing results in 
multiple transcripts encoding different 
isoforms. 
    
+ P < 0.1; * P <0.05; ** P < 0.01 
1 Gene coverage was based on genetic variation present in the HapMap database build 18. 
2 Short description adapted from gene ontology description provided in the UCSC genome graph tool. 
3 P values reported by QTDT using command WEGA (additive model), tests for association given linkage on a specific locus. 
4 P values reported by QTDT using command WEGD (dominant model), tests for association given linkage on a specific locus. 
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Table 3. Genotype analysis and linear mixed model for CD53 SNP rs6679497, assuming a dominant model of 
association 
Study N (11)1 Log(TNFα) N (12)1 Log(TNFα) N(22)1 Log(TNFα)  P LMM2 P LMM3 
GARP 86  3.90 178 3.86 99 3.85 0.013* 
85-Plus 312 4.01 564 3.97 238 3.97 0.032* 
0.001** 
+ P < 0.1; * P <0.05; ** P < 0.01 
1 11=homozygote common allele; 12=heterozygote; 22=homozygote rare allele 
2 Modelling dominant effect, corrected for familial relationship, age, sex and BMI 
3 Modelling dominant effect combining studies, corrected for study differences in level, familial relationship, age, sex and BMI 
 
Association analysis of rs6679497 to OA 
No significant association was observed for CD53 rs6679497 when GARP subjects (cases) 
were compared to subjects of the Leiden 85-Plus study as controls using the dominant 
model (adjusted for age, sex and BMI, P=0.142), indicating that TNFα QTL locus did not 
confer susceptibility to OA. 
 
Discussion and conclusion 
 
Through a genome wide linkage scan we were able to identify SNP rs6679497 in CD53 of 
which the minor allele associates to lower innate TNFα levels. It can be hypothesized that 
the specific genotype of rs6679497 predisposes or protect its carriers from diseases and 
disorders in which TNFα plays a substantial role. Previously, it was shown that TNFα does 
not play a major role in the onset of OA8 and in line with this hypothesis we were unable to 
show associations of rs6679497 to OA as defined in the GARP study. 
CD53 codes for cluster of differentiation 53, a leukocyte surface antigen. The protein 
family which this cell surface glycoprotein belongs to is known to complex with integrins, 
cellular components involved in cell-cell and cell-matrix interactions. CD53 deficiency has 
been linked to recurring infectious diseases caused by bacteria, fungi and viruses27, 
susceptibility to these might be increased for carriers of the minor allele of rs6679497. The 
protein is implicated in elevated cellular glutathione in response to LPS activation and may 
increase cell survival under UV-B and oxidative conditions28. Furthermore, treatment of 
neutrophils with TNFα down-regulates the presence of the CD53 antigens on the cell 
surface through a proteolytic mechanism29. This indicates that the protein may play a 
substantial role in cellular stability and the inflammatory response to adverse conditions. 
Furthermore, the protective effect of ligated CD53 on the cellular surface may help specific 
tumors to escape from programmed cell death30. Although rs6679497 or any of the SNPs in 
its LD block are investigated for effects on the expression levels or protein function, the 
gene is under strong genetic control31 and genetic variation might have a role in tumor 
biology or other diseases. Such a relation can readily be elucidated through investigation of 
this marker SNP in cancer cohorts. Furthermore, in a study which characterizes leukocytes 
from normal and rheumatoid arthritis (RA) patients, CD53 was found to be elevated on the 
RA lymphocytes surfaces32. Investigating the role if this gene in relation to this and other 
TNFα driven diseases later in life may show protective effects of the rs6679497 minor 
allele. 
The SNP CD53 rs6679497 resides within the intron of the gene, which shows low levels of 
conservation across species, and it is in an LD-block across several introns and exons 
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encompassing at least 23 other intron SNPs(recorded in the HapMap phase 1 & 2 data). 
Several transcripts are known as recorded in the UCSC database (accession number 
ENSG00000143119), however, only a proportion of these will actually be translated into a 
protein. Given the current level of total variation tagging (52%) it is likely the SNP is only 
a proxy marker in LD with a causal (functional) polymorphism which could have a more 
obvious implication to the gene regulation or protein stability and functioning. This is 
substantiated by the fact that the CD53 SNP explains only part of the linkage as determined 
in QTDT analyses (results not shown). To find the true functional variant, a more detailed 
analysis of this gene by sequencing or SNP saturation is necessary. Alternatively, in our 
candidate gene approach we may have missed additional genetic variation at the loci of 
interest because of a knowledge bias on both the presence and role of genes at these loci. 
Although it was shown previously that the IL1 cluster haplotypes were associated to IL-1ß 
bio-availability33,34, we observed no evidence of linkage on the genetic loci for the 
respective cytokines’ genes, the IL-1 gene cluster on chromosome 2, IL-10 on chromosome 
1 or TNF on chromosome 6. Possibly, the genetic variation in LPS stimulated cytokine 
levels explained by these loci is not readily detected by linkage analysis, which is known to 
be most suitable to detect loci that explain a major part of genetic variation. Furthermore, 
our linkage analyses of innate IL-1β, IL-1Ra and IL-10 levels in general revealed only 
moderate linkage peaks up to a LOD score of 2.5. More likely as was shown in a previous 
study33, particularly the estimate of innate IL-1ß production upon LPS stimulation may not 
be entirely independent of the OA disease status, possibly by sensitization of the Toll-like 
receptor pathways as a result of disease activity35 or otherwise sensitization of the response 
by lymphocytes, which may have interfered with the current linkage analysis by 
introducing cohort heterogeneity or bias. In the linkage analyses, we checked whether the 
levels in the GARP study sample were normally distributed to facilitate powerful linkage 
analysis using the variance component option. The innate levels of IL-1β, IL-10 and TNFα 
were normally distributed, whereas innate IL-1Ra levels were normally distributed after 
removal of 1 extreme value, which did not alter the linkage analysis results (data not 
shown). The use of Merlin-Regress21 which may be more appropriate for use in highly 
selected samples showed a similar pattern of LOD scores for all traits, with slightly lower 
maximum LOD scores. It remains possible that the observed association only occurs in 
middle aged and elderly, therefore, further searches for genetic loci that influence the ex 
vivo innate cytokine profiles may benefit from the use of healthy young subjects in these 
searches. 
Following a genome wide linkage analysis, association analysis of positional candidate 
gene SNPs within the 1-LOD-drop interval of a linkage peak, we show a consistent 
association of SNP rs6679497 in CD53 to innate TNFα levels in both the GARP study (P = 
0.013) and the confirmation cohort consisting of Leiden 85-Plus participants (P= 0.032). A 
dominant linear mixed model analysis on combined data from the GARP and Leiden 85-
Plus study showed that the minor allele of this SNP associated to a highly significantly 
lower innate TNFα level independent of age and sex effects. In diseases with a large TNFα 
component such as inflammatory bowel disease or rheumatoid disorders, the minor allele of 
rs6679497 might exert a protective effect in susceptibility or severity. 
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fine mapping of initial linkage peaks. 
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Abstract 
 
Objective: To gain more insight into the role of genetic variation of the C-reactive protein 
(CRP) gene in serum CRP levels and osteoarthritis (OA).  
Methods: Serum high sensitive CRP (S-HsCRP) levels were measured in the Genetics of 
osteoARthritis and Progression (GARP) study. Furthermore, to assess genetic variation of 
the CRP gene, genotypes of five tagging single nucleotide polymorphisms were assessed in 
the GARP study and a random control sample.  
Results: A significant and consistent relation between S-HsCRP levels and observed 
haplotypes was identified. Additionally, a CRP haplotype, which also associated to a 
significantly higher expected phenotypic mean S-HsCRP level, was associated to severe 
hand OA. This haplotype was tagged by a single nucleotide polymorphism (rs3091244). 
Carriers of this allele have an increased risk for the presence of severe hand OA with an OR 
of 2.3 (95% confidence interval 1.2 to 4.3, p=0.009). 
Conclusions: A haplotype of the CRP gene, associated to high basal S-HsCRP level, is also 
associated to severity of hand OA, indicating that innate high basal S-HsCRP levels may 




Osteoarthritis (OA) is characterised by degeneration of articular cartilage and remodelling 
of bone. Heritability estimates range from 30% to approximately 80%, depending on the 
specific joint affected or the number of joint sites involved. Although OA pathophysiology 
lacks a large-scale inflammatory process, there may be a low-grade systemic inflammatory 
component1,2. Chondrocytes are known to respond to pro-inflammatory stimuli by 
decreasing synthesis of extracellular matrix components and increasing synthesis of 
metalloproteinases. As such, an innate low-grade pro-inflammatory state of the body may 
affect susceptibility to the onset of OA2, or may exacerbate progression once the OA 
disease process is initiated3. 
S-HsCRP is a sensitive marker of both low-grade4 and acute phase systemic inflammation5. 
Previously, CRP haplotypes (locus 1q23.2) were identified that may partly explain the 
heritability of S-HsCRP levels (52%)6,7. Furthermore, S-HsCRP level, as a marker of low-
grade inflammation, has been associated to a range of OA features4,8-10. In the current study 
we would like to investigate whether the innate inflammatory state, as expressed by the S-
HsCRP level and variation at the CRP gene, contributes to the presence of OA in the 
Genetics of osteoARthritis and Progression (GARP) study.  
 
Material and methods 
 
The GARP study 
The ongoing GARP study consists of 191 (n=382) Caucasian sibling pairs affected with 
symptomatic OA at multiple sites. For the current paper genotypic information was 
available for 381 individuals and S-HsCRP levels for 353 individuals. Detailed descriptions 
of the phenotypes and inclusion criteria can be found elsewhere11. In the current paper 
“quantitative hand OA” was defined by the number of hand joints (out of 20 scored) with 
radiographic OA (ROA). “Severe hand OA”, as a qualitative measure, was defined by 
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presence of seven or more ROA affected hand joints, equalling 27% of subjects. Partners of 




Haplotypic means were assessed using Thesias V3.113. Haplotypic associations were 
analysed by testing the particular haplotype to the remaining haplotypes. To assess the 
strength of association to severe hand OA a logistic regression analysis was performed in 
STATA. In this analysis robust standard errors were estimated from the variance between 
sibling pairs to compensate for familial relationships within GARP14. A linear mixed model 
was tested to assess association between S-HsCRP levels and OA phenotypes, with family 
numbers included as random variables to model possible familial effects. Differences in 
allele frequencies between subjects with and without severe hand ROA were calculated by 





For 381 GARP subjects and 739 controls genotypes were completed. Baseline 
characteristics of these are shown in table 1. 
 
Table 1. Characteristics of the GARP study and the random control population. 
 GARP Control 
Total, no. 3821 739 
Women, no. (%) 311 (81.4) 429 (58.1) 
Age, median (range) years 59.7 (42.7-79.4) 58.3 (30.0-79.0) 
BMI2, median (range) 26.0 (19.1-46.5)  
S-HsCRP3, mean (SE of mean) 3.63 (0.29)  
S-HsCRP3, median (range) 1.83 (0.21-56.8)  
Mean number of affected hand joints (range) 4.62 (0-20)  
Subjects with severe hand OA (%) 103 (27)  
1 GARP study sample consists 191 sibling pairs, for 381 subjects DNA was available. 
2 BMI stands for Body Mass Index in kgm-2 
3 S-HsCRP stands for Serum High Sensitive CRP level in mgl-1, numbers are calculated for subjects with S-HsCRP 
levels available (N=353). In all analysis logarithmic transformed values of S-HsCRP were used. 
 
C-reactive protein gene haplotype frequencies 
As is shown in table 2, six common haplotypes were resolved with frequencies ranging 
from 0.01 to 0.33. The frequencies in GARP and the control population were comparable 
with the frequencies observed by Carlson et al6. No significant differences in haplotype 
frequencies were found between the GARP study and the control population. 
 
Association of C-reactive protein haplotypes with high sensitive C-reactive protein 
serum levels 
Figure 1A shows the mean log(S-HsCRP) level for each haplotype within the GARP 
sample (n=353). Haplotype 1 (H1) has a significant lower (p=0.009), whereas haplotype 
7/8 (H7/8) has a significant higher (p=0.02) contribution to the mean log(S-HsCRP) level. 
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Table 2. Assigned haplotype frequencies, expected phenotypic means of log(S-HsCRP) for GARP and the control 
sample haplotype frequencies. 
Haplotype
1





GARP 7 0.01 - - Other3 
Control 7 0 - - 
GARP 46 0.07 -0.074 0.084 Haplotype 1 
CACAA Control 97 0.07 - - 
GARP 199 0.28 0.123 0.030 Haplotype 2 
CAGAA Control 389 0.26 - - 
GARP 7 0.01 0. 0.10 Haplotype 3 
CAGGA Control 10 0.01 - - 
GARP 188 0.27 0.137 0.034 Haplotype 4 
CAGGG Control 423 0.29 - - 
GARP 217 0.31 0.217 0.026 Haplotype 5 
TTGGA Control 482 0.33 - - 
GARP 42 0.06 0.306 0.062 Haplotype 7/8 
AAGGA Control 70 0.05 - - 
GARP 706 1 - - TOTAL 
Control 1478 1 - - 
1 Genotyping was done on a Sequenom™ platform with slightly modified protocols. SNPs used to resolve haplotypes with gene 
positions relative to AFF449713 and minor allele frequencies were rs3091244 , 1440 (C>T>A, 0.315/0.057), rs1417938 1919 
(A>T, 0.248), rs1800947 2667 (G>C, 0.063), rs2808630 5237 (A>G, 0.268) and rs2808628 (A>G, 0.336). The latter SNP is in 
close LD to SNP rs1205 used in the original study by Carlson et al.6, of which the haplotype nomenclature used was adapted. 
2 Levels displayed are the expected haplotypic contribution to the mean log(S-HsCRP) level of carriers as calculated by the 
Thesias program. In individuals the expected S-HsCRP level is determined by the contribution of the 2 carried haplotypes. The 
Thesias program does not allow correction for familial relationship. 
3 Rare haplotypes with frequencies below 0.01 were pooled as “other”. 
 
Association of C-reactive protein haplotypes with osteoarthritis subtypes 
A significant positive association of H7/8 was observed for increasing number of ROA 
affected hand joints. As shown in fig 1(B), quantitatively a significantly higher (p=0.04) 
expected mean number of affected hand joints was observed for H7/8 (mean 3.88, SE 0.66) 
as compared with remaining haplotypes (mean 2.23, SE 0.13). 
Subsequently it was investigated whether H7/8 associated to GARP subjects with severe 
hand ROA (n=103). The frequency of H7/8 in severe hand ROA cases (frequency 0.096) 
was significantly higher as compared with the other subjects of GARP (frequency 0.04, 
p=0.038) and as compared with a random control sample (n=739, frequency 0.046, 
p=0.016). H7/8 is discriminated by the rarer allele of single nucleotide polymorphism 
rs3091244. Carriers of the A allele have an increased risk (p=0.009) of severe hand OA as 
compared with the random controls with a crude OR of 2.3, 95% CI 1.2 to 4.3. The 
frequency of the A allele does not allow robust recessive model testing. Adjusting for age 
and/or body mass index in the logistic regression did not change the extent or significance 
of the genotypic risk.  
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Figure 1 (a) Expected mean log(S-HsCRP) levels of common (frequency 
>0.05) CRP haplotypes in the GARP sample for which both genotype and 
S-HsCRP levels were available (N=353). H1 to H7/8 represent clades of 
the phylogenetic tree of the SNPs in the CRP gene, where H1 is the most 
recent and H7/8 represent the most ancient split (See Carlson et al.6). (b) 
Expected mean number of affected hand joints of common (frequency 
>0.05) CRP haplotypes in the GARP study (N=381). 
Error bars represent standard error of the mean, * P < 0.05 ** P < 0.01 
 
There were no significant differences in CRP haplotype frequencies between subjects with 
and without involvement of knee, hip, spine or extent of clinical features of OA expressed 
by WOMAC (Western Ontario MacMaster osteoarthritis questionnaire) scores. 
 
Association of serum high sensitive C-reactive protein levels and osteoarthritis 
Moderate positive associations were observed between S-HsCRP levels and both knee 
ROA (p=0.06) and WOMAC scores for pain and stiffness (p=0.08). Both these 
associations, however, were merely due to their association with high body mass index. We 
could not asses direct association between S-HsCRP levels and hand OA. 




S-HsCRP serum levels and CRP gene haplotypes were assessed in the GARP study to 
investigate the role and extent of low inflammatory processes in the development of 
symptomatic OA at multiple joint sites. We show that mean and median basal S-HsCRP 
levels observed in the GARP study as a whole are not within acute phase ranges6, 
confirming that OA is not a large-scale inflammatory disorder. 
Furthermore, CRP haplotypes, with frequencies ranging from 0.01 to 0.31, showed a 
specific pattern of mean S-HsCRP level. An increasing S-HsCRP level from H1 to H7/8 
was observed, which coincides with the phylogenetic clades of the CRP gene6. This may 
indicate an evolutionary development towards low innate S-HsCRP levels. Although the 
mean S-HsCRP level in GARP was slightly higher (approximately 1 mg/l) the specific 
haplotypic pattern was strikingly similar to the one identified in the study of Carlson et al. 
in healthy individuals6. Of these haplotypes, H1 had a significantly lower and H7/8 had a 
significant higher expected mean S-HsCRP level as compared with other haplotypes. 
Furthermore, an allele that discriminates H7/8 associated to the mean number of affected 
hand joints with an OR of 2.3 for the presence of severe hand OA. The low-grade pro-
inflammatory profile brought about by this single nucleotide polymorphism may affect 
cartilage homeostasis and may ultimately lead to a systemic form of OA. As in many 
genetic studies we cannot exclude the possibility of false positive findings due to multiple 
testing; however, this is the first report of an association of a CRP gene polymorphism to 
OA. Punzi et al9 showed an association of erosive hand OA and high serum CRP levels. 
Despite the association between H7/8 of both S-HsCRP levels and hand OA, no direct 
association between S-HsCRP levels and hand ROA could be established in this study. 
Initial associations observed between, S-HsCRP levels and knee ROA and WOMAC scores 
in the GARP study were merely confounded by body mass index15. Our study may either 
not provide enough power to show associations between S-HsCRP profiles and other OA 
features, or acute phase responses, by, for example, obesity, may obscure association of 
disease and innate ongoing low-grade inflammatory effects. Furthermore, it is known that 
S-HsCRP may not cover the whole spectrum of inflammatory processes, therefore, future 
studies may focus also on other inflammatory mediators in relation to OA. To show 
absence of familial effects in our data the analyses were repeated in unrelated individuals of 
the GARP study yielding similar results (supplemental figure 1). 
Together the current study confirms that genetic contribution of the low-grade basal CRP 
levels may be attributed to haplotypes of the CRP gene. Furthermore, it is shown that a 
specific systemic low-grade pro inflammatory profile may predispose to severe hand ROA 
among subjects of the GARP study as compared with healthy individuals. To investigate 
further the role of CRP in OA of the hand, upcoming progression data in this study may 
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Supplemental Figure 1. (a) Expected mean log(S-HsCRP) levels of 
common (frequency >0.05) CRP haplotypes in the unrelated GARP 
sample for which genotype and S-HsCRP levels were available 
(N=187). (b) Expected mean number of affected hand joints of 
common (frequency >0.05) CRP haplotypes in the unrelated GARP 
sample (N=191). 
Error bars represent standard error of the mean, ** P < 0.01 
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Abstract 
 
Objective: Investigating the association between plasma levels of cytokines and 
chemokines, Selenoprotein S (SELS) gene variation and osteoarthritis (OA) subtypes. 
Methods: The GARP study consists of 191 sibling pairs with symptomatic OA at multiple 
joint sites. We have measured plasma levels of 17 cytokines and chemokines and genetic 
variation at the SELS gene. 
Results: Nine out of 17 serum markers could be assessed quantitatively, whereas eight 
markers were assessed qualitatively. Principal component analysis (PCA) on the 
quantitatively assessed markers and serum high sensitive C-reactive protein (S-HsCRP) 
revealed that three components underlie 61% of the total plasma variation. Three single 
nucleotide polymorphisms (SNPs) in the SELS gene revealed four common haplotypes, one 
of which, GAG (frequency 3.5%) showed significant association to an anti-inflammatory (P 
= 0.019) and acute phase related (P = 0.036) component. OA subtype analysis showed that 
one component (mainly representing chemokine variation) was significantly associated to 
hand OA and disc degeneration (P = 0.029 and P = 0.010 respectively) as well as a physical 
component score (PCS) (P = 0.042). The CRP related component also showed a strong 
association to the PCS (P = 0.007). SELS haplotypes showed no association to OA subtypes 
in the GARP study. 
Conclusion: Genetic variation in the SELS gene associates to components representing 
inflammatory signaling. Another component, representing chemokine variation, showed 
association to hand OA and disc degeneration in the GARP study indicating chemokines 




Osteoarthritis (OA) is a common joint disease and an important cause of pain and disability 
in the general population. Elucidation of common pathways that are involved in the onset 
and progression of the disease will assist in the development of new drug targets and 
provide a better management of this disabling condition in the future. Several studies have 
shown that genetic factors play an important role in OA etiology1,2. Although OA is not 
regarded to be an inflammatory disease, there is increasing evidence for the involvement of 
an innate low grade systemic inflammatory component which may partly explain the 
genetic susceptibility3-7. More specifically, support for the hypothesis that local variation in 
cytokine levels in the joint may influence OA onset and progression is found in the 
catabolic effects of pro-inflammatory cytokines, and the protective effects of anti-
inflammatory cytokines in articular cartilage8,9. Gene expression studies have shown that in 
OA cartilage several cytokines and chemokines are highly expressed10-12. The recent 
introduction of multiplexed cytokine assays facilitates sensitive measurements of different 
cytokines using small amounts of valuable sample material from different origins. This 
sensitive technique allows investigation of the basal levels of chemokines and cytokines in 
plasma in relation to the ongoing disease processes for diseases where, as in OA, no 
pronounced and obvious inflammatory component is present. 
In a previous study, Curran et al. showed that subjects can be characterized by a high 
(proinflammatory) or low (noninflammatory) plasma cytokine profile depending on a 
common promoter single nucleotide polymorphism (SNP) -105G > A (rs28665122) in the 
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Selenoprotein S (SELS) gene. A significant association of this SELS SNP was observed 
specifically with higher plasma levels of tumor necrosis factor alpha (TNFα), interleukin 
beta (IL1b) and interleukin 6 (IL6)13. SELS is a widely expressed protein involved in 
maintaining the functional integrity of the endoplasmatic reticulum (ER) by participating in 
the removal of misfolded proteins and regulating the cellular redox balance. SELS 
inhibition by siRNA revealed that a functionally impaired ER leads to activation of 
numerous pro-inflammatory cytokines mediated by nuclear factor kb (NF-kb) activation13. 
In a cohort of patients with intestinal inflammation, there was no association to the SELS 
locus, however, the pro-inflammatory allele associated to a high serum CRP levels in Crohn 
Disease patients with active disease14. Finally, SELS polymorphisms associated with 
coronary heart disease and ischemic stroke15. These studies trigger the question whether 
SELS gene variation also influences inflammatory responses and the etiology of OA. 
Hence, we set off to map the plasma levels of 17 cytokines and chemokines by use of a 
multiplexed bead array system in subjects with symptomatic OA at multiple joint sites of 
the GARP study. We tested whether SELS gene variation influenced these inflammatory 
plasma mediators and OA, and whether these markers associated to OA subtypes and 
severity.  
 
Materials and methods 
 
The GARP study 
The GARP study consists of 191 sibling pairs. All participants have symptomatic OA at 
multiple sites in the hand or OA at two or more joint sites of four joint sites examined16. 
Symptomatic OA was determined following the American College of Rheumatology 
recommendations17-19 whereas radiographic OA (ROA) was scored according to 
Kellgren/Lawrence20. Details on the GARP OA phenotype and inclusion criteria can be 
found in previous publications16. Physical functioning was assessed with the physical 
component score (PCS), a subscore of the Dutch validated RAND 36-item Health Survey. 
This questionnaire covers health related aspects including social functioning, role 
limitations, mental health and vitality21,22. A higher score on the PCS indicates a better 
physical functioning. For the current study we used the proportionate ROA score based on 
the presence of ROA at each joint location and on the number of joints with ROA identical 
as described previously. In short, scores 0, 1 and 2 represent respectively no, uni- and 
bilateral hip and knee OA for these joint sites. The hand ROA score (0-2) represents 
subjects with, respectively, 0-2, 3-6, and ≥7 hand joints affected out of 20 scored. For 
spinal discus degeneration (DD) score (0-2) represents subjects with DD at respectively 0-
2, 3-5 and ≥6 levels out of 11 levels scored23. Hand OA following the ACR criteria17 was 
analyzed in addition to the ROA criteria. Genomic DNA was extracted from peripheral 
blood leukocytes using standard protocols. Written informed consent as approved by the 
ethical committee was obtained from all subjects in the GARP study. 
 
Serum and plasma collection and measurements 
For each participant of the GARP study a morning serum and EDTA plasma sample was 
collected. Samples were processed within 4 h upon collection and stored at -80˚C until 
measurement. Serum high sensitive C-reactive protein (S-HsCRP) was assayed earlier24. A 
17-plex bead assay provided by Bio-RAD was used to measure plasma levels of cytokines 
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and chemokines on a Luminex platform. Intra assay variation was estimated at 6.2%. The 
standard protocol was adjusted using twice the indicated amounts of plasma sample in half 
the amount of sample buffer to increase signal in the measurements. On each plate 10-15% 
of samples were in duplicate, in which no inconsistencies were observed. For calculation of 
z-scores the average value of duplos was used as a single value. For cytokines and 
chemokines with less than 60% of the fluorescence levels above background noise, a 
qualitative measure of detectable vs not detectable level was used (qualitative analysis, 
QL). For cytokines and chemokines with more than 60% fluorescence levels above 
background noise, z-scores of fluorescence levels were calculated per plate (quantitative 
analysis, QT). In the principal component analysis (PCA) individuals with missing values 
in five or more out of nine cytokine/chemokines measurements were excluded (N = 13). 
For the analyzed individuals remaining missing values were given the specific marker mean 
score. Sample distribution was random per plate on a total of eight plates. 
 
Genotyping 
In the current study three SNPs of the SELS were genotypes selected from the original 
paper of Curran et al.13. SNP positions relative to translation start of the SELS gene are -105 
(G > A, rs28665122), +3705 (G > A, rs4965814), and +6218 (A > G, rs9874). SNPs were 
measured using hME™ chemistry on a matrix assisted laser adsorption/ionization time-of-
flight mass spectrometry (MALDI-TOF) Mass Spectrometer (Sequenom Inc., San Diego, 
CA, USA). Assays were designed using the Sequenom MassARRAY Assay Design 
software (version 3.1). Assay conditions were standard conditions as described earlier25. In 
addition to the genotypes obtained by the Sequenom for rs28665122, a Taqman assay 
(Applied Biosystems, Foster City, California, United States) was performed to deal with 
low genotyping success rates this SNP using the Sequenom technique. Primers used for the 
ABI-genotyping were: forward primer 5’GGGTCGGCCTGCGA and reverse primer 
5’CTTCCGGTGCGCTCCTA, probes were 5’TGGCCGGGACCAC labeled with VIC and 
5’TTGGCCA GGACCAC labeled with FAM. Assays were run on a 7900HT (Applied 
Biosystems) according to the manufacturers specifications. Genotypes of both techniques 
were used in addition to each other where necessary and were used as a control where both 
techniques provided reliable genotypes. No inconsistencies were observed between 
techniques for the reliable genotypes. 
 
Statistical analysis 
PCA was applied to reduce the correlated data of the cytokines and chemokines plasma 
levels. Subjects (N = 341) with available levels of S-HsCRP and with >4 out of nine 
quantifiable markers were entered in the PCA analysis. In PCA analyses random missing 
data (see Table 2) was replaced by mean values. Both empirical criteria (percentage of 
variance explained by factors and Eigen values > 1) and interpretability were used to 
determine the number of factors. We explored the interpretability of these factors after 
applying a Varimax rotation with Kaiser Normalization. The loading score of each variable 
onto the individual factors represents the contribution of that variable to the variance 
observed in the resulting factor. For analysis only individual variable contributions of >0.4 
qualified for loading a component26. A factor loading represents the linear relationship 
(Pearson correlation under Varimax rotation) between a variable and a factor. 
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In order to assess the relationships between OA characteristics, genetic variation at the 
SELS gene and the clusters of cytokines and chemokines, a mixed model regression 
analyses was performed. To investigate the individual associations, subject specific 
regression scores of each extracted cluster were used as dependent variable and age, sex, 
BMI (Body Mass Index) and all OA subtypes as co-variables. OA features and subtypes 
tested were specific ROA scores as defined previously; knee (0-2), hip (0-2), hand (0-2) 
and spinal DD (0-2)24 and the PCS derived from the SF36 questionnaire. Furthermore, for 
each linear mixed model analysis family identity numbers (representing family relations) as 
random variables in order to model the familial dependencies that might occur for the 
levels. 
Genotype distributions of SELS SNPs were checked by use of the HWE program available 
at http://linkage.rockefeller.edu. Thesias V3.1 was used to assess linkage disequilibrium 
between the SNPs and to assess the expected haplotypic contribution to a mean quantitative 
measure in carriers of a specific haplotype27. Quantitative measures analyzed by use of 
Thesias are e.g., the subject specific regression scores as determined by the PCA analyses. 
In individuals the expected quantitative measure is determined by the contribution of the 
two carried haplotypes. The Thesias program allows for adjustments of co-variables but not 
for familial relationship. Chi square analyses were performed to test for association of 
individual SNPs or proportionate ROA scores to the qualitatively analyzed cytokines and 
chemokines. P-values are unadjusted to multiple testing. Analyses were done in SPSS 




Cytokine and chemokine measurements 
Characteristics of the GARP study are displayed in Table 1. For all participants of the 
GARP study cytokine and chemokine levels were analyzed in a plasma sample by use of a 
17-plex bead array system. Table 2 shows cytokines and chemokines measured and the 
percentage of samples with levels above detection limit. In nine instances (see Table 2) we 
were able to assess a semi quantitative measure by the use of z-scores reflecting relative 
plasma levels. For the remaining eight instances (see Table 2), plasma levels were analyzed 
in a qualitative matter (detectable vs not detectable). 
 
Association analysis of cytokine/chemokine levels with OA features 
Nine cytokines and chemokines and S-HsCRP were analyzed in a quantitative manner, the 
remaining eight cytokines and chemokines were qualitatively analyzed. In the 
quantitatively analyzed cytokine and chemokine z-scores we observed substantial 
correlations (Supplementary Table 1). In addition to the association between S-HsCRP and 
BMI shown previously24, Supplementary Table 1 also shows the frequently observed 
association between BMI and plasma IL6 levels. GARP subjects in the highest BMI 
quartile (BMI > 29.1 kg/m2) had an OR of 1.7 (95% C.I. 1.01-2.82) to reside in the highest 
quartile of IL6 plasma levels (P = 0.042) when corrected for age, sex and familial 
relationship. To reduce the redundancy between the markers to more independent 
components in which these variables cluster, a PCA including all inflammatory markers for 
which a quantitative measure was available (see Table 2) and S-HsCRP was performed. 
Table 3 shows the three components that were extracted. The coefficients depicted in Table 
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3 explain how well each individual marker is represented within the clusters. The marker 
levels of IL2, IL6, Granulocyte CSF Q3 (GCSF) and IL10 loaded together on the first 
component, explaining 34.1% of the total variation in the GARP study. 
 
Table 1. Study characteristics of the 382 patients with OA at multiple joint sites 
(GARP study). 
 N (%) Mean (sd) range 
Women 312 (81.7) - - 
Age (years) 382 (100) 60.27 (7.54) 42.66 – 79.44 
BMI (kgm-2) 379 (99.2) 27.00 (4.67) 19.10 – 46.48 
S-HsCRP (mgl-1) 354 (92.7) 3.63 (5.43) 0.21 – 56.80 
Clinical hand OA 271 (70.7) - - 
PCS SF36 375 (98.2) 54.02 (21.10) 8.75-98.75 
ROA Score
1
 0 1 2 
Knee 232 90 60 
Hip 275 56 51 
DD 125 181 76 
Hand 169 110 103 
BMI body mass index, S-HsCRP serum high sensitive C-reactive protein, ROA radiographic 
osteoarthritis, DD discus degeneration, PCS physical component scale 
1All subjects were affected by OA at multiple joint sites. The scores 0, 1 and 2 represent a 
proportionate OA score, as described earlier24. In genetic analysis hip and knee replacements 
(respectively 38 and 8) were considered as OA, numbers indicated are patients with diseased joints 
at sampling, or had replacements within the year prior to sampling) 
 
Table 2. Cytokines and chemokines in the 17-plex bead assay with levels above 
background noise per cytokine and chemokine. 
Cytokine / Chemokine N Detectable (%) Analysis 
Interleukin 1β 107 28.3 QL 
Interleukin 4 26 6.9 QL 
Interleukin 12 90 23.8 QL 
Interleukin 13 172 45.5 QL 
Interleukin 17 25 7.1 QL 
Interferon γ 179 47.4 QL 
Tumor Necrosis Factor α 165 43.4 QL 
Granulocyte Monocyte CSF 144 37.8 QL 
Interleukin 2 234 61.6 QT 
Interleukin 5 222 58.4 QT 
Interleukin 6 374 98.4 QT 
Interleukin 7 274 72.1 QT 
Interleukin 8 359 94.5 QT 
Interleukin 10 327 86.1 QT 
Granulocyte CSF 248 65.3 QT 
MCP-1 377 98.9 QT 
MIP-1β 375 98.4 QT 
QL stands for a qualitative analysis, QT stands for a quantitative analysis, CSF stands for colony 
stimulating factor., MCP stands for Monocyte Chemotactic Protein, MIP stands for Macrophage 
Inflammatory Protein. 
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Table 3. Individual factor cytokine scores extracted by principal 
component analysis of 10 inflammatory markers measured in blood. 
Component1 1 2 3 
IL2 0.839   
IL6 0.815   
Granulocyte CSF 0.764   
IL10 0.594   
IL7 0.561  0.474 
MCP-1  0.799  
IL8  0.799  
MIP-1β  0.765  
S-HsCRP   -0.747 
IL5   0.585 
Total variation explained 34.1% 15.7% 11.6% 
1Extraction Method: Principal Component Analysis in which missing values 
were replaced by mean levels.  
IL stands for Interleukin, CSF stands for colony stimulating factor, MCP 
stands for Monocyte Chemotactic Protein, MIP stands for Macrophage 
Inflammatory Protein, S-HsCRP stands for serum high sensitive C-reactive 
protein. 
 
Component 2 is determined by three chemokines MCP (Monocyte Chemotactic Protein), 
IL8 and MIP (Macrophage Inflammatory Protein), explaining 15.7% of the variation, 
whereas the third component is determined by S-HsCRP, IL5 and IL7 explaining 11.6% of 
the variation. It should be noted that S-HsCRP has a negative value in the third component 
(Table 3), indicating that on average, within subjects there is an inverse relation between S-
HsCRP levels and IL7 and IL5. 
Subsequently the relationship between the three components as dependant variables and the 
presence of OA characteristics (Table 1) as co-variables was investigated by mixed model 
regression analysis. The upper section of Table 4 shows that component 2, consisting of 
chemokines IL8, MIP and MCP, has significant negative associations to hand ROA score 
(beta = -0.14 P = 0.039) and to disc degeneration ROA score (beta = -0.22 P = 0.005), 
independent of age, sex and BMI. This implies that subjects with high chemokine levels 
have lower hand ROA and DD scores. In addition, component 2 showed a similar 
association to subjects that had hand OA according to the ACR criteria (beta= -0.26; P = 
0.024, data not shown). When analyzing the relationship of the components to the PCS 
derived from the SF36 a significant negative association of component 2 (P = 0.035) and a 
positive association to component 3 (P = 0.004) was observed, independent of sex, age and 
BMI (Table 4, lower section). This indicates that subjects with high chemokine levels 
experience more functional impairment whereas subjects with high IL7, IL5 and low S-
HsCRP levels experience less functional impairment. The association of PCS to component 
2, however, appeared not independent of the hand ROA scores (data not shown). In each of 
the mixed models significant associations with BMI were observed for component 1 
(positive, P = 0.049), for component 2 (negative, P < 1 x 10-5) and component 3 (negative, 
P < 1 x 10-5). In the qualitatively analysis of the cytokines no significant associations were 
observed for OA subtypes (data not shown). 
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Table 4. Effect sizes (β) of the linear relationships 
between the extracted principal components (1-3) 
reflecting variation at plasma chemokines / cytokine 
levels and OA characteristics (ROA score, clinical 
symptoms) of the subjects of the GARP study sample. 
OA characteristics Components1 
Radiographic OA 1 2 3 
Hip ROA score 0.079 0.098 0.035 
Knee ROA score -0.079 0.043 -0.088 
Hand ROA score 0.030 -0.140* -0.042 
DD ROA score 0.002 -0.223* -0.060 
SF36 outcome 1 2 3 
PCS 0.001 -0.006* 0.007** 
1Component 1 contains IL2, GCSF, IL6, IL10 and IL7. 
Component 2 contains MCP, IL8, MIP and component 3 
contains S-HsCRP (negative), IL5 and IL7. Data was analyzed 
using mixed model regression analyses with the components as 
dependent variable and as co-variables the joint specific ROA 
scores (top) or the PCS (bottom) in addition to age, sex and 
BMI. PCS stands for physical component score. 
* P < 0.05 ** P < 0.01. 
 
SELS gene variation, inflammatory parameters and OA 
In the GARP study we could not confirm the previously reported association of rs28665122 
with TNFα, IL1-b and IL6 plasma levels by Curran et al.13. 
The influence of the SELS SNPs on the cytokine and/or chemokine levels, as expressed by 
the three components, was investigated by haplotype analysis since high linkage 
disequilibrium was observed between the three SELS SNPs (D’ > 0.8). As shown in Table 
5, four common haplotypes with frequencies over one percent were observed similar to a 
Finnish population15. A significant association was observed between haplotype GAG 
(frequency 3.5%) and component 1 (P = 0.019). Since component 1 reflects variation in 
IL2, IL6, GCSF and IL10 levels this association indicates that carriers of this haplotype 
have higher levels of the cytokines in this component. Upon further investigation, this 
association appeared to be mainly driven by IL10 variation (univariate analysis P = 0.001). 
In addition, the GAG haplotype shows association to component 3 (P = 0.036) containing 
IL5, IL7 and inversely S-HsCRP. This association appeared to be mainly attributable to S-
HsCRP levels in the component (univariate analysis P = 0.002). These associations were 
independent of BMI, age and sex. The fact that both components associate to the GAG 
haplotype indicates some interrelation between the haplotype and these components. We 
were not able to asses association between SELS SNPs or haplotypes and OA subtypes.  
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Table 5. Haplotype frequencies within the GARP study with their mean haplotypic contribution to the component 
scores as extracted from the data of 9 cytokines/chemokines and CRP. 






GGA 638 (83.5) -0.25 (-0.61 - 0.11) -0.27 (-0.58 - -0.05) 0.85 (0.56 - 1.15) 
AAG 81 (10.6) -0.22 (-0.65 - 0.20) -0.39 (-0.79 - 0.00) 0.83 (0.48 - 1.18) 
GAG 27 (3.5) 0.68 (0.24 - 1.10)* -0.23 (-1.06 - 0.61) 1.98 (1.35 - 2.61)* 
GAA 10 (1.3) -0.68 (-2.57 - 1.21) -0.37 (-1.38 - 0.64) 0.92 (0.29 - 1.54) 
other 8 (1.1) - - - 
Total 764 (100)    
* BMI adjusted P-value <0.05 for contribution of the haplotype GAG to the component score as compared to the other haplotypes 
as determined by THESIAS. C1 component 1, C2 component 2, C3 component 3. 1Scores displayed are the expected haplotypic 
contribution (independent of the BMI effects) to the mean “principle component regression score” of subjects calculated by the 
Thesias program. In individuals the expected level is determined by the contribution of the 2 carried haplotypes. The THESIAS 
program does not allow correction for familial relationship. Alleles are in the following order of SNPs in the SELS gene -105 
(rs28665122G>A), +3705 (rs4965814G>A), and +6218 (rs9874A>G). 2Component 1 reflects variation of IL2, IL6, GCSF and 
IL10 levels, component 2 reflects variation of chemokines MCP, IL8 and MIP and component 3 reflects variation of HsCRP 
(negative), IL5 and IL7. 
 
Discussion and conclusion 
 
In inflammation driven diseases high circulating plasma levels of pro-inflammatory 
cytokines and S-HsCRP are present well above detection limits of current methods and 
readily used for diagnostic and prognostic purposes28. Cytokines, however, are known to 
exert their wide ranged actions also in very low concentrations. The recent introduction of 
multiplexed cytokine assays facilitates simultaneous measurements of multiple cytokines. 
However, the described absence of a large scale upregulation or strong association of any of 
the measured cytokines or chemokines in the plasma of subjects with familial OA at 
multiple joint sites indicates that, in blood plasma, these markers are not sufficiently 
suitable to monitor the ongoing OA process. Synovial fluid measurements might better 
reflect the ongoing disease process since it better reflects the cytokine activities near the 
site where the disease is mainly active29. PCA analyses of cytokine/chemokines 
measurements revealed 3 components. component 1 reflects variation at IL2, IL6, GCSF 
and IL10 levels, component 2 reflects variation at chemokines MCP, IL8 and MIP and 
component 3 SHsCRP (negative), IL5 and IL7. The components seem to reflect different 
ongoing (patho) physiological processes identified by subjects underlying the components. 
Component 1 may be classified as a marker of ongoing anti-inflammatory signaling based 
on the strong involvement of IL10, whereas component 2 shows chemokine signaling and 
component 3 reflects more acute phase related signaling. The observed (Supplementary 
Table 1) and known correlation of IL6 to S-HsCRP is, with the current setting in the PCA 
(Eigen values > 1), not reflected in the components since together they do not explain 
sufficient amount of the variation. 
We found a significant negative association for component 2 to hand OA and DD as well as 
to the SF36 derived PCS. This indicated that especially the subjects that exhibit high 
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functional impairment and have low hand ROA scores have high chemokine levels. It 
should be noted that, by definition of the GARP selection criteria, subjects of the GARP 
study with low hand or disc ROA scores have OA at other joint sites. We could not, 
however, attribute the negative association of hand and disc ROA to positive effects caused 
by these other joint sites. Given these results it appears the higher levels of chemokines act 
protective in hand and disc OA among subjects of the GARP study. The strong association 
of the PCS to component 3 including S-HsCRP might reflect impairment of physical 
functioning mediated or reflected by the individual markers in this component, the observed 
effects are independent of BMI and ROA status. Due to the relative large amount of 
missing values in the IL5, IL7 and GCSF data we may have missed specific associations 
with these markers. 
Previously, it has been shown that there is a major upregulation of chemokines in human 
OA affected cartilage12. Our analysis show that, amongst subjects of the GARP study, this 
upregulation might be less pronounced in subjects with hand OA and disc degeneration of 
the spine as compared to the other subjects, when correcting for all involved joint sites. 
This may reflect a different pathophysiological process underlying hand OA and disc 
degeneration as compared to knee and hip OA. This needs to be further explored in other 
cohorts of OA patients and especially using control samples. 
Given the earlier found associations of SELS SNPs to inflammatory factors measured in 
blood13, we expected to find associations of cytokines and chemokines especially to 
rs28665122, however, no direct associations of these levels or presence of these cytokines 
and chemokines were observed for variation at the SELS gene. A recent paper of Seiderer et 
al.
14 also showed no confirmation of the association for rs28665122 to cytokine levels in a 
study including patients with intestinal inflammation. As compared to the study in intestinal 
inflammation patients, however, Curran et al. used a more sensitive method of measuring 
cytokines. Seiderer et al. did observe an association of the pro-inflammatory allele to higher 
serum CRP levels in a subgroup of Crohn disease patients with higher signs of disease 
activity14. In our study, possibly the association to either cytokines or S-HsCRP for 
rs28665122 is not observed due to a smaller sample size or upregulation of these cytokines 
by the ongoing disease processes is not sufficient to show the genotype effect as observed 
by Seiderer et al.. However, haplotype association analyses revealed a specific SELS 
haplotype (GAG, 3.5%) significantly associated to components of increased IL10 blood 
levels and decreased S-HsCRP levels, confirming that the SELS gene variation may 
interfere with or affect the homeostasis of the inflammatory pathways. 
In the PCA individuals with missing values in five or more out of nine 
cytokine/chemokines measurements were excluded (N = 13). For the analyzed individuals 
remaining missing values were given the specific marker mean score. Although we could 
not readily detect the cause of values being missing most likely these occurred due to bad 
sample quality or assay errors and less likely due to individuals being out of range. 
Performing PCA using a list wise case selection (using only cases with all markers 
available), replacing missing values by the lowest observed value, imputation of the 
missing values by use of regression analysis or by use of multiple imputation using a 
winMICE implemented EM algorithm30 did not affect formation of components or 
subsequent associations (data not shown). The components reported should be considered 
robust. The effect of the familial dependencies on the component formation is considered to 
be minimal as the total number of pairs in the dataset cancels out possible intra sibling pair 
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correlations. This is strengthened by the results of an analysis of the data using only one 
member per sibling pair (data not shown) which shows highly similar component and 
scores. 
Moreover, by excluding individuals with over four out of nine missing values we may have 
excluded individuals with a particular low-inflammatory profile. Finally, missing values in 
the qualitatively analyzed cytokines may likewise have been subject to possible 
misclassification of individuals due to bad sample quality, assay errors or measurement 
problems. 
Since OA patients are likely to use drugs which alter the immune system we explored 
whether the use of NSAIDs significantly influenced our results. In a split analysis for use vs 
no use of NSAIDs the formation of the components in the PCA showed no major changes, 
except for the third component in NSAID users where IL5 and IL7 disappeared. The 
described subsequent associations remained present in both separate datasets (data not 
shown). 
In earlier investigations of the GARP study, we have found that S-HsCRP levels are 
independently associated to a CRP haplotype7,13 and by the occurrence of the closely 
related factors knee ROA, BMI and high WOMAC scores24. In the current study we show 
that a SELS haplotype is additionally influencing the S-HsCRP level. When we fitted a 
mixed model with S-HsCRP as dependent variable and as co-variables the CRP haplotype 
H7/8, SELS haplotype GAG, and the factor representing knee ROA, BMI and WOMAC24, 
it was shown that all three consistently and independently influence the S-HsCRP level. In 
this model, the SELS haplotype (GAG) significantly decreased (beta = -0.42; P = 1.9 x 10-5) 
S-HsCRP levels in carriers whereas the S-HsCRP haplotype H7/8 (beta = 0.14; P = 0.08) 
and the PCA component (beta = 0.14; P = 1.6 x 10-9) increased S-HsCRP level. 
The strength of the GARP study lies in the availability of extended clinical and radiological 
data of OA features for four joint sites. Furthermore, demographic data for the participants 
is available, as well as additional familial information, a range of biological fluids and 
DNA. A downside for this study is, however, that the sample size is relatively small for 
genetic studies and no synovial fluid samples and control samples of healthy individuals are 
available for the cytokine measurements in this study. 
The analysis of a range of cytokines as measured in blood has not shown any strong 
associations of one single cytokine to OA features; however, a component comprised of 
several chemokines did show association to OA in smaller joints and PCS. Another 
component which has strong involvement of S-HsCRP shows a highly significant 
association to this PCS, indicating physical impairment might be reflected or mediated by 
the markers in this component, independent of presence of specific ROA subtypes. Future 
measurements of chemokines and related signaling proteins in synovial fluid may shed 
more light on the origin of this association. Long term effects of lower circulating SHsCRP, 
cytokine or chemokine levels might be reflected by OA progression. Upcoming follow up 
data in the GARP study will reveal whether these inflammatory parameters associate to 
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 HsCRP IL2 IL5 IL6 IL7 IL8 IL10 GCSF MCP MIP BMI 
HsCRP  7.1x10-1 2.3x10-1 1.7x10-4 3.8x10-1 1.4x10-2 6.9x10-1 1.5x10-2 4.2x10-1 6.0x10-1 1.0x10-6 
IL2 -0.03  9.1x10-1 1.0x10-6 1.0x10-6 2.1x10-2 1.0x10-6 1.0x10-6 0.09 0.01 4.3x10-1 
IL5 -0.08 0.01  1.3x10-2 4.0x10-4 5.8x10-2 3.2x10-5 1.5x10-1 1.3x10-2 3.1x10-3 4.5x10-1 
IL6 0.20 0.58 0.17  1.0x10-6 1.0x10-6 1.0x10-6 1.0x10-6 1.0x10-6 1.0x10-6 2.0x10-3 
IL7 -0.05 0.38 0.27 0.32  7.9x10-3 1.0x10-6 3.8x10-4 1.2x10-4 1.4x10-6 4.4x10-1 
IL8 0.13 0.16 0.13 0.33 0.17  1.0x10-6 2.7x10-2 1.0x10-6 1.0x10-6 6.6x10-1 
I10 0.02 0.36 0.29 0.47 0.33 0.42  1.3x10-5 1.0x10-6 1.0x10-6 6.8x10-1 
GCSF 0.16 0.42 0.11 0.38 0.26 0.14 0.28  5.0x10-2 9.0x10-2 3.7x10-1 
MCP 0.04 0.11 0.17 0.27 0.23 0.49 0.37 0.12  1.0x10-6 2.4x10-1 
MIP -0.03 0.17 0.20 0.28 0.29 0.49 0.38 0.11 0.50  1.5x10-1 
BMI 0.36 0.05 -0.05 0.16 -0.05 0.02 -0.02 0.06 0.06 0.08  
 Spearman’s correlations  
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Abstract 
 
Objective. Functional characterization of OA risk polymorphism rs225014 at DIO2 and 
respective thyroid signaling in OA and non-OA cartilage 
Design. Alleles of the OA risk single nucleotide polymorphism rs225014, a T to C 
transition coding for a Thr92Ala substitution in type II deiodinase (D2) at DIO2 were 
analyzed for differential allelic expression in mRNA extracted from OA cartilage. 
Immunohistochemical staining of D2 and associated thyroid signaling proteins was 
performed on OA and non-OA cartilage. 
Results. We assessed allelic expression imbalance of DIO2 using rs225014 in cartilage of 
OA patients heterozygous for the polymorphism. A significantly higher amount of 
expression was observed for the OA-associated C allele relative to the T allele in 17 out of 
20 donors, indicating that cis-acting regulatory effects may underlie the association of this 
polymorphism to OA. Furthermore, to assess the ongoing thyroid signaling in cartilage we 
have used immunohistochemistry to stain anatomically “healthy” non-OA and OA affected 
human cartilage for D2, type III deiodinase (D3) and thyroid hormone receptors alpha and 
beta. We show that in OA affected cartilage thyroid hormone signaling is substantially 
increased and that this increase overlaps with an increasing Mankin score, indicative of 
increasing thyroid hormone activity with increasing cartilage damage. 
Conclusion. Our analyses show activated thyroid signaling in OA cartilage, which should 
be considered detrimental to cartilage homeostasis. In addition, disruptions of cartilage 
homeostasis may be augmented by the increased expression in cartilage of the OA risk C 




Osteoarthritis (OA) is a common, degenerative disease of the articulating joint that causes 
pain and disability. Currently, treatment of the disease is limited to pain suppression with 
no drug yet available that can effectively slow down or reverse the disease process. 
Ultimately, affected joints need replacement thereby imposing a considerable burden on 
patients and on health care systems1. Previously, using genome wide linkage and 
association approaches in multiple centers across different ethnic groups, we identified 
DIO2 as a gene harboring susceptibility for OA. A DIO2 haplotype consisting of SNPs 
rs225014 and rs12885300 showed consistent association to OA2. DIO2 codes for type II 
deiodinase (D2), which is expressed in specific tissues where it has a vital role in the 
regulation of intracellular thyroid hormone 3,5,3'-triiodo-L-thyronine (T3) levels through 
deiodination of inactive thyroid hormone thyroxine (T4)
3,4. In the growth plate, 
chondrocytes express D2 in the transition to terminal differentiation which is controlled at 
least in part through T3 levels
5-7. Functional differences of DIO2 in this process might lead 
to subtle differences in joint shape or bone composition, which could predispose to OA as a 
result of a lifelong exposure to overt biomechanical factors on the articular cartilage. 
Furthermore, later in life functional differences of DIO2 might enhance the predisposition 
for articular chondrocytes to turn hypertrophic, thereby initiating or augmenting their 
release from the maturational arrest that sustains chondrocytes in articular cartilage8. No in 
vivo cartilage studies specifically aimed at D2 have been performed, however DIO2 RNA 
transcripts were shown to be up regulated in OA cartilage as compared to healthy 
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cartilage9,10. Here we investigated the role of D2 in articular cartilage and OA by functional 
genomic research of patient and control cartilage. 
We assessed putative differential allelic expression (DAE) of rs225014 alleles by allelic 
discrimination assays in OA cartilage RNA. Although the OA risk allele of DIO2 rs225014 
codes for a Thr92Ala substitution in the protein, to date no compelling evidence has been 
reported showing that this substitution has a major influence on protein function11-14. 
Possibly, the polymorphism acts as a cis regulatory element or is in linkage disequilibrium 
with such an element; earlier studies of OA cartilage samples have indicated the presence 
of polymorphic cis regulatory elements on alleles of OA associated genes such as FRZB, 
GDF5 and BMP515-17. DAE effects are present throughout the genome18 and potentially 
contribute to the observed genetic associations seen for many common complex 
phenotypes, including OA. It could be that for DIO2 such modest but persistent imbalances 
of specific allelic expression differences throughout life renders subjects more susceptible 
to OA. 
To explore ongoing thyroid hormone signaling in OA affected and non-OA cartilage, 
immunohistochemical (IHC) staining of proteins involved in thyroid signaling was 
performed. In addition to D2 staining we studied the thyroid hormone receptors alpha 
(THRA) and beta (THRB), which bind activated T3 and which can subsequently alter gene 
expression through activation of thyroid responsive elements on DNA. Furthermore, D3 
was included in our IHC analyses since this protein is responsible for inactivation of 
thyroid signaling through the conversion of T4 into inactive reverse T3 as well as active T3 
into inactive T2
3. Altogether these proteins may indicate the activity of the ongoing thyroid 
hormone signaling. 
 
Materials and methods 
 
Subjects. 
For DAE assessment, subjects undergoing a joint replacement as a result of primary OA 
were recruited at the Nuffield Orthopaedic Centre (Oxford, UK; Nuffield samples, N=7) 
and at the Leiden University Medical Centre (Leiden, the Netherlands; LUMC samples, 
N=13). Ethical approval for the study was obtained from appropriate ethics committees. 
Immediately upon joint replacement the affected articular cartilage was collected, frozen in 
liquid nitrogen and subsequently transferred to -80˚C for storage. For the 
immunohistochemical assessment of thyroid hormone signaling proteins 6 non-OA and 11 
OA affected hip cartilage tissues embedded in paraffin were retrieved from the archives of 
the department of pathology, LUMC (Leiden, the Netherlands). Non-OA samples 
originated from subjects receiving a replacement after a hip fracture. 
 
Nucleic acid isolation and rs225014 genotyping. 
To enable isolation of RNA and DNA the frozen cartilage samples were powderised using a 
Retsch Mixer Mill 200 with continuous liquid nitrogen cooling. RNA isolation was 
performed using Qiagen RNAeasy Midi kits as described earlier19, the first wash 
flowthrough in this isolation was used for subsequent DNA isolation. RNA was stored in 
precipitated state after addition of 1/10th volume of sodium acetate (3M, pH 5.2), linear 
acrylamide to an end concentration of 10 µgl-1 and 2 volumes of ethanol. cDNA was 
synthesized by use of random hexamer primers as described earlier17. The wash flow-
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through collected during RNA isolation was used to isolate genomic DNA by addition of 
1/10th volume of sodium acetate (3M, pH 5.2) and 3 volumes of ethanol. The precipitated 
DNA was washed and resuspended in 60 µl of milliQ water. To assess rs225014 genotypes, 
genomic DNA was PCR amplified using forward primer 5’-
TACCACACTCTATTAGAGCC-3’ and reverse primer 5’-
CACACACGTTCAAAGGCTAC-3’ targeted at a 586 basepair DIO2 fragment 
encompassing rs225014. The PCR products were incubated with restriction enzyme RsaI at 
37˚C for 3 hours and genotypes were visually called by running the digested PCR products 
on a 3% agarose gel showing cut (TT), uncut (CC), or both (TC) fragments of DNA. Only 
heterozygous subjects were included in this study. 
 
Differential allelic expression assessment. 
cDNA and genomic DNA from heterozygous samples were subjected to a 15 µl PCR 
amplification using 20 and 5 replicates respectively using forward primer 5’- 
ATGCTGACCTCAGAGGGACT-3’ (cDNA) or 5’-AGTGGCAATGTGTTTAATGTGA-
3’ (genomic DNA) and reverse primer for both PCR reactions 5’-
CACACACGTTCAAAGGCTAC-3’. Amplification products were treated with 
exonuclease and shrimp alkaline phosphatase to an end volume of 18 µl prior to further 
processing. For the Nuffield samples 1.8 µl of SNaPshot Multiplex Ready Reaction Mix 
(Applied Biosystems), 0.1 µl of HPLC-purified extension primer (5’-
CACTGTTGTCACCTCCTTCTG-3’) and 0.2 µl milliQ water was added to 1.2 µl of PCR 
product in an extension reaction. The samples were subjected to 25 cycles of extension 
consisting of 10 seconds at 96˚C, 5 seconds at 50˚C and 30 seconds at 60˚C, upon which 
the sample was cooled to 4˚C. 1 µl of extended product was added to 10 µl of Hi-Di 
formamide containing 120LIZ size standard (Applied Biosystems). Analysis of the 
fluorescence for C and T alleles (TAMRA and ROX label respectively) in each sample was 
performed on an ABI 3130xl Genetic Analyzer (Applied Biosystems) and data was loaded 
in Genemapper 3.1 for quality control, genotype calling and exporting fluorescence peak 
height values. Samples which failed to amplify in the assays or cDNA samples which were 
outliers in the respective samples replicate group of normalized log transformed peak 
height ratios were omitted from further analysis. For the LUMC samples cleaned PCR 
products were diluted 500 times and 1 ul was used as template in a Taqman realtime assay 
(C__15819951, Applied Biosystems) in a final volume of 5 µl. The dilution was aimed to 
reach a cT threshold after 15-20 cycles of amplification. Samples were subjected to 10 
minutes of denaturation at 95°C, and 40 cycles of 92°C for 15 seconds and 1.25 minutes at 
60°C on an ABI Prism 9700HT (Applied Biosystems). Reactions were followed real-time 
and after cycling an end measurement of fluorescence levels was performed. 
 
Statistics. 
Peak height ratio of allele C over T from each individual cDNA sample was normalized 
using the pooled genomic DNA samples (1:1 ratio of allelic presence) to account for 
technical variation in fluorescence of the labels. Per centre, the log transformed normalized 
peak height ratio per cDNA sample replicate series were analyzed for differential allelic 
expression by a two-tailed Mann-Whitney non parametric test (SPSS Version 16.0) against 
all genomic DNA samples.  
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Histological assessment. 
HE and toluidine blue staining were used to score all samples according to Mankin et al.20 
by 3 observers blinded towards the clinicopathological data. In this scoring system ranging 
from 0 (no signs of OA) to 15 (total destruction of cartilage layer) samples are scored for 
microscopic OA features such as decreased proteoglycan content reflected by decreased 
toluidine blue staining, hypo- or hypercellularity, clonal expansion of chondrocytes, 
tidemark crossing by blood vessels and cartilage (micro)fractures. 
 
Immunohistochemistry. 
Antibodies and protocols used for antigen retrieval and blocking are listed in Table 1. 
Immunohistochemistry (IHC) was performed according to standard procedures as described 
previously21. Visualization was performed by Powervision incubation followed by 
incubation in 0.05% diaminobenzidine tetrahydrochloride (Sigma) with 0.01% hydrogen 
peroxide and hematoxylin was used to counterstain the slides. 
 
Table 1. Characteristics of antibodies used in the IHC analysis of thyroid signaling proteins. 





Antigen retrieval Block Dilution 













citrate none 1:8000 
























 1Antibodies were kindly provided by Prof. Dr. T.J. Visser22 (Department of Endocrinology, Erasmus University MC, Rotterdam, 
the Netherlands). 
 
Immunohistochemical staining for D2, THRA and THRB in the superficial, middle and 
deep cartilage layers was scored for nuclear and cytoplasmic localization whereas D3 was 
scored for cytoplasmic and extracellular staining by scoring 0 (no staining), 1 (weak or 




Differential allelic expression analysis 
Characteristics of the Nuffield and LUMC OA cartilage samples are listed in table 2, all 
individuals included in this study were heterozygous for rs225014. The relative abundance 
of rs225014 alleles was analyzed by use of a SNaPshot extension reaction (Nuffield 
samples) or Taqman realtime PCR assay (LUMC samples) on the amplified target region 
encompassing rs225014. Table 2 lists the relative ratios of the T and C alleles for rs225014 
for each cDNA sample, with the pooled genomic DNA ratios serving as the 1:1 allelic 
reference. Six of the 7 Nuffield samples demonstrated a higher expression of the C allele 
and this was a significant observation (P ≤ 0.01) for 4 of these 6 samples. In an overall 
analysis of all 7 Nuffield samples allele C was significantly more abundantly present in the 
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cDNA samples (P<0.01). All 13 LUMC samples demonstrated a significantly higher 
expression of the C allele (Table 2, Figure 1). Overall therefore, 17 of the 20 samples 
studied (85%) demonstrated a significantly higher expression of the C allele of SNP 
rs225014 relative to the T allele. The mean percentage of relative difference was 17% and 
36% for the Nuffield and LUMC samples, respectively. The DAE observations were 
consistent between different skeletal sites and between the two genders. None of the tested 
genomic DNA samples showed significant deviations from allelic balance when tested 
against the remaining genomic DNA samples (data not shown). 
 
Table 2. Characteristics of the 20 OA cartilage samples studied and the results of the allelic expression analysis. 




1 Female 71 Left Knee 11 (55) 3 (60) 0.97 0.269 
2 Female 72 Left Knee 11 (55) 5 (100) 1.28 <0.01 
3 Female 65 Right Knee 20 (100) 5 (100) 1.14 0.052 
4 Female 75 Right Knee 20 (100) 4 (80) 1.24 <0.01 
5 Female 53 Left Knee 19 (95) 2 (40) 1.07 0.268 
6 Male 88 Right Hip 17 (85) 5 (100) 1.29 <0.01 
Nuffield 
samples 
7 Male 61 Right Knee 19 (95) 5 (100) 1.18 <0.01 
8 Female 70 Right Shoulder 18 (90) N/A 1.30 <0.01 
9 Female 79 Left Hip 19 (95) 5 (100) 1.26 <0.01 
10 Male 61 Right Hip 20 (100) 5 (100) 1.29 <0.01 
11 Female 59 Right Hip 16 (80) 4 (80) 1.34 <0.01 
12 Male 71 Right Hip 19 (95) 4 (80) 1.32 <0.01 
13 Female 75 Left Knee 20 (100) 5 (100) 1.33 <0.01 
14 Female 78 Right Hip 19 (95) 5 (100) 1.25 <0.01 
15 Female 75 Left Hip 20 (100) 5 (100) 1.60 <0.01 
16 Female 79 Right Knee 20 (100) 5 (100) 1.38 <0.01 
17 Male 56 Left Hip 17 (85) 5 (100) 1.36 <0.01 
18 Female 62 Right Hip 18 (90) 5 (100) 1.41 <0.01 
19 Female 79 Right Hip 17 (85) 5 (100) 1.42 <0.01 
LUMC 
samples 
20 Female 62 Shoulder 17 (85) 5 (100) 1.42 <0.01 
 
 
1 Age at time of joint replacement  
2 cDNA PCR measurements passing quality control (max. 20) 
3 Genomic PCR measurements passing quality control (max. 5) 
4 Mann-Whitney non parametric test (cDNA’s per individual versus genomic DNA samples per centre) 
 
 
Figure 1. Individual log transformed peak height ratios for SNP rs225014 alleles C over T. Genomic ratios are 
indicated by black circles whilst mRNA ratios are indicated by triangles. + P < 0.1, ** P < 0.01 
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Immunohistochemical assessment of thyroid hormone signaling 
To assess ongoing thyroid hormone signaling in OA cartilage as compared to non-OA 
cartilage we stained hip cartilage sections for D2 as well as for D3, THRA and THRB. 
Characteristics of the donors used are shown in Table 3. The non-OA subjects who received 
a joint replacement as a result of a fracture were on average significantly older than subjects 
who received a joint replacement as a result of OA. Using the Hematoxilin and Eosin (HE) 
staining and toluidine-blue staining (Figure 2A, A’ and B, B’ respectively) a Mankin score 
was assessed for each sample to quantify the OA damage. Four out of five non-OA samples 
had both HE and toluidine blue slides available and a mean Mankin score of 2.4 ranging 
from 0 to 7 whereas 11 OA samples had a statistically significant higher mean Mankin 
score of 9.5, ranging from 5 to 12 (Table 3). For the OA samples we observed increased 
collagen type X staining in all layers of the cartilage, indicating that chondrocytes in the 
OA samples have turned hypertrophic (Figure 2C, C’). Immunohistochemical stainings for 
THRA stained nuclear and equally throughout all samples and was not included in further 
analyses. Most nuclei and cytoplasm of chondrocytes throughout the different layers of 
cartilage in OA samples stained strongly for D2 whereas only some of the nuclei and 
cytoplasm in the non-OA cartilage stained positive for D2 (Figure 2D, D’). D3 staining 
showed increased numbers of positive cells in the OA affected areas of samples as 
compared to non-OA samples (Figure 2E, E’). For THRB most samples stained positive, 
however, the OA affected samples showed a more pronounced staining of nuclei and cells 
throughout all layers of the cartilage (Figure 2F, F’). 
 


























1 F 62 5 1/0 2 1/1 12 M 93 0 1/0 1 0/1 
2 F 68 7 2/2 2 2/2 13 F 79 1 1/2 2 1/1 
3 M 51 9 2/1 2 1/1 14 F 79 2 1/1 1 1/1 
4 M 54 9 1/0 0 1/1 15 F 79 2 2/2 2 1/1 
5 F 61 9 2/2 2 2/2 16 F 71 7 1/1 1 2/2 
6 F 59 10 2/1 2 2/1 17 F 82 n/a 1/1 2 1/1 








   
8 F 72 11 1/2 1 1/1        
9 F 38 11 2/2 2 2/2 
10 M 80 11 2/1 2 2/2 








   
*t-test p-value < 0.01 
1 nuc: nuclear staining score cyto: cytoplasmic staining score; 0 no staining, 1 weak to moderate staining, 2 strong staining. 
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Figure 2 A-F non-OA cartilage samples & A’-F’ OA cartilage samples. A/A’ HE staining of non-OA (A) and 
OA (A’) sample. B/B’ Toluidine-blue staining of non-OA (B) and OA (B’) sample. C/C’ Collagen type X 
staining of non-OA (C) and OA (C’) sample. D/D’ D2 staining of non-OA (D) and OA (D’) sample. E/E’ D3 
staining of non-OA (E) and OA (E’) sample F/F’ THRB staining of healthy(F) and OA (F’) sample. Tol-
toluidine blue ColX-Collagen Type X. Magnifications 50x, insets 200x. 
 
Together the increased presence of thyroid signaling proteins throughout all layers of the 
cartilage indicates that in OA cartilage thyroid signaling is upregulated. We semi-
quantitatively assessed the staining presence and intensity for these three proteins 
throughout the different cartilage layers (Table 3) and observed that samples with higher 
Mankin scores were on average inclined to stain more abundantly and at higher intensity 
for these proteins and that, as opposed to the non-OA group in which mainly superficial 
staining was observed, the stainings in the OA group were present in all cartilage layers. 
The age of the subjects had no obvious relation to the Mankin grade or to the staining 
intensities within the groups of OA and non-OA subjects.  
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Discussion 
 
Using transcript SNP rs225014 we were able to demonstrate that DIO2 is subject to highly 
significant and consistent differential allelic expression (DAE) in OA cartilage with the OA 
risk C allele being more abundantly expressed in OA cartilage than the T allele. A large 
majority of the individuals studied demonstrated deviation from allelic balance indicating 
that the polymorphism itself or a polymorphism in strong linkage disequilibrium (LD) with 
it is the cis-acting regulatory polymorphism. This may act by influencing the transcription 
rate of DIO2 or the stability of the DIO2 mRNA. Previously, in smaller samples sizes the 
RNA expression of DIO2 was shown to be up regulated in OA cartilage9,10 and it is possible 
that this is partly accounted for by homozygote carriers of the OA risk C allele who, from 
our previous genetic studies, would be expected to be more prevalent in an OA cohort. It is 
possible that homeostatic feedback mechanisms ensure that the expression of the DIO2 
encoded protein D2 is balanced in response to different genotypes, and that challenges to 
this homeostasis mean that the response generated by the OA risk allele C is relatively 
strong and causes an aberrant thyroid signal in the cartilage. Investigation of DIO2 DAE in 
non-OA cartilage samples may elucidate whether the observed allelic imbalance depends 
on the conditional use of cis regulatory elements in response to OA cartilage disease 
activity or whether it is independent of this and therefore functions as a conventional risk 
factor. Putatively underlying the observed association of the risk allele to OA is the 
possibility that during early development the increased expression of the C allele might lead 
to subtle changes in joint morphology and aberrant joint loading, thereby predisposing to 
OA. Alternatively, the maturational arrest of the chondrocytes may diminish as a function 
of age and allow for activation of genes not active in healthy cartilage. A greater expression 
of the risk allele C might increase the speed of cartilage degradation towards clinical 
outcomes as described earlier2,23. The fact that in the Netherland’s LUMC study all samples 
showed significant DAE, whereas in the UK Nuffield study 4 of 7 samples showed 
significant DAE might be ascribed to the more sensitive technique used in the LUMC 
study. It is reassuring to note however that the use of two different techniques to measure 
allelic expression imbalance both highlighted relative increased expression of the C allele 
of rs225014. Since both studies comprised an analysis of Caucasian individuals from 
Northern Europe it is unlikely that genetic differences would account for the fact that not all 
of the UK samples demonstrated DAE. Having demonstrated DAE at DIO2, deep 
sequencing of this gene and of its proximal regulatory elements is now merited to identify 
additional variants that might also regulate DIO2 expression and contribute to OA 
susceptibility. 
Our DAE results suggest that the increased expression of the risk C allele of rs225014 
might underlie the association of the polymorphism to OA. Relevant to the increased 
signaling of the allele is whether in OA the presence of the D2 protein in cartilage is 
aberrant. To assess D2 protein levels in OA cartilage as compared to non-OA cartilage we 
performed immunohistochemical analysis of the protein in cartilage specimens obtained 
from OA and non-OA joints. To get a more complete overview of ongoing thyroid hormone 
signaling we also stained these sections for the thyroid hormone inactivating protein D3 and 
THRA as well as THRB, which are responsible for activation of gene transcription through 
thyroid responsive elements on the DNA. THRA was present in all samples and cartilage 
layers, indicating at least a baseline thyroid signaling activity; however we did not observe 
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differences between the OA and non-OA samples. In bone, THRA and THRB isoforms 
appear to have different properties24, however little is known about their roles in cartilage. 
To establish the roles of these specific receptors in cartilage additional research is 
warranted. We observed increased protein expression of D2, D3 and THRB through all 
layers of osteoarthritic cartilage, indicative of increased thyroid hormone signaling in OA 
cartilage as compared to non-OA, “healthy” cartilage from hip fracture patients. This 
increased signaling may preferentially act through the THRB receptor. Although it is 
unclear whether the observed changes in thyroid signaling are causal or merely a marker of 
the ongoing OA disease process, the up-regulation of thyroid signaling would be 
detrimental to cartilage homeostasis: the increased presence of thyroid hormone related 
proteins in cartilage could antagonise the maturational arrest of chondrocytes and promote 
phenotypic changes resembling those observed in the growth plate23, contributing to 
cartilage loss. The increase in presence of the thyroid hormone inactivating protein D3 may 
be considered as a response to the D2 induced increased levels of active thyroid hormone 
T3. In some of the superficial layers of the cartilage from the non-OA patients moderate D2, 
D3 and THRB staining is observed, indicating that random variation of thyroid hormone 
proteins is present, possibly as a result of the aging process or as a reflection of the higher 
availability of oxygen in this layer that may predispose it to dedifferentiation. The OA 
samples show a more abundant staining in all layers of the cartilage and in cellular 
components. One of the non-OA samples that stained positive for D2 had a Mankin score 
of 7, which is indicative of moderate cartilage damage, although OA was not recorded in 
the medical history of this subject. We were unable to stain the thyroid hormones T4 and T3 
in the cartilage sections to confirm the ongoing thyroid signaling by these hormones 
directly. This may be attributable to the fact that the concentration for effective signaling of 
thyroid hormones can be very low. Future analysis of additional samples with both affected 
and preserved cartilage regions as well as non-OA, “healthy” cartilage samples at different 
ages may help to elucidate whether the observed increased thyroid signaling precedes 
cartilage damage or whether this occurs once the damage is present. 
Overall, our analyses showed that activated thyroid signaling in OA cartilage may play a 
role in OA etiology, and that this may be augmented by the increased expression in 
cartilage of the OA risk C allele of DIO2 SNP rs225014. Given the role of activated thyroid 
hormone T3 during endochondral ossification, where it enhances the terminal maturation of 
chondrocytes, the described increased presence of D2 protein and increased expression of 
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4.1 Discussion of results 
Osteoarthritis (OA) is a complex disorder with a large heritable component. Research into 
OA etiology remains a priority to provide adequate therapy for those affected by the disease 
and to overcome the involved socio-economic burden imposed by the large loss of working 
force and health care cost. Several risk genes or loci such as FRZB, GDF5, DIO2 and 
chromosome 7q22 have been identified to date1,2; however, these genes only explain a 
small part of the heritability of the disease. Recent collaborative efforts have proven fruitful 
in increasing power and should be considered as a positive impulse in OA research2,3. 
These collaborations in addition to previous studies have resulted in the identification of 
several OA susceptibility genes, in which two pathways appear consistent contributors to 
the disease. The evidence for genetic contribution to the etiology is most convincing for 
genes in the inflammatory pathway as well as for genes regulating developmental processes 
in skeletal formation and maintenance1,4(Chapter 1). We investigated groups of genes 
belonging to both pathways; Chapter 2 covered studies where we investigated the relation 
between genes, inflammatory markers and OA, mainly in the GARP study. The strength of 
the GARP study is that for these subjects a complete collection of biomaterials such as 
DNA, serum and urine is available, in addition to extended OA data and demographic data. 
Subjects are selected for a familial history of OA, thus enriching for the genetic component 
of OA. This cohort allows investigation of the role of genes in both levels of markers as 
well as the role of these genes to disease susceptibility. Chapter 3 covered studies that 
characterize thyroid signaling in general and specifically genetic variation at DIO2, which 
play a role in endochondral ossification during development and for which there is evidence 
for their involvement in OA5. These functional studies have paved a road for functional 
genomics research for current and future OA susceptibility loci. 
 
4.2 Inflammation in OA 
In our studies described in Chapter 2 we tried to investigate the highly complex interaction, 
illustrated in Figure 1, between inflammatory mediators and OA. In particular, we aimed to 
distinguish the putative causal (genetic) inflammatory associations influencing OA 
susceptibility and associations to inflammatory mediators that may mark the ongoing 
disease process. The general working hypothesis investigated was based on the role of 
cytokines in normal cartilage metabolism. These pro- and anti-inflammatory cytokines act 
on the chondrocyte and thereby regulate ongoing catabolic and anabolic processes during 
both the maintenance and repair of cartilage (Figure 1). Subtle changes in the delicate 
balance between these mediators might confer a risk to OA and identification of cause and 
effect beyond an established association is one of the challenges when OA and 
inflammation are studied. We approached this by measuring levels of inflammatory 
mediators, testing for genetic variation that might be associated to these mediators and 
establishing the relation of these variants and OA, touching Mendelian randomization6 at a 
small scale. Ex vivo cytokine production profiles of LPS stimulated lymphocytes were 
measured which represent an innate marker of an individual’s inflammatory potential to 
respond to inflammatory challenges throughout life. In addition, circulating levels were 
used as a measure of current inflammatory status and ongoing disease processes. Genetic 
configuration of the innate and circulating levels was used to identify possible underlying 
mechanisms of these inflammatory mediators which might influence OA onset or disease 
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characteristics. We expected to find high levels of pro-inflammatory cytokines and genetic 





















Figure 1. Processes of pro- and anti-inflammatory signaling on the chondrocyte and resulting extracellular 
matrix (ECM) turnover. 
 
4.2.1 OA, innate IL-1β bio-availability and haplotypes of the IL-1 gene cluster 
In line with the general hypothesis, it was previously shown that on average the subjects of 
the GARP study had a higher innate IL-1β and lower innate IL-10 levels than controls7,8. 
Although not always consistent and determined in relatively small studies, it was also 
shown that several genetic variants within the IL-1 gene cluster and more consistently the 
IL1RN gene may be responsible for part of the variation in this heritable innate ex vivo 
cytokine production upon LPS stimulation9,10. Subsequently, association studies 
investigated whether these potential functional aspects of the IL-1 gene cluster 
polymorphisms may explain part of the genetic susceptibility to OA. Compelling 
associations of the IL-1 gene cluster are reported for knee, hip and hand OA11-16, however 
others failed to confirm these associations17,18. We have combined ex vivo IL-1β bio-
availability measures upon LPS stimulation, a large part of the genetic variation at the IL-1 
gene cluster and OA disease status in one single study population (the GARP study). In this 
study, haplotype 2-2-1 (frequency 0.22) covering the IL1RN block showed a significant 
lower bio-availability calculated by the ratio of IL-1β and IL-1Ra as compared to the other 
IL1RN haplotypes and this haplotype associated to subjects (25%) with the highest number 
of ROA affected joints. Surprisingly, this result would imply that low innate IL-1β bio-
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availability predisposes to OA, or that an OA protective effect is associated to high innate 
IL-1β bio-availability. We hypothesize that when repair of minor damage to the cartilage is 
needed, a sufficient IL-1β induced release of ECM degrading enzymes is needed for proper 
clearing of the damaged cartilage. A lower IL-1β bio-availability might leave damaged 
cartilage strands thereby compromising matrix integrity, whilst the inflammatory signals 
arising from the sensed cartilage damage remain19. Alternatively, feedback loops in IL-1β 
orchestrated pathways need a high enough stimulus to initiate an anti-inflammatory 
feedback with subsequent anabolic ECM producing processes20,21. The finding of 
association of lower innate IL-1β bio-availability to OA severity among subjects of the 
GARP study seems contrasting with respect to a previous observation which showed that 
subjects of the GARP study as compared to healthy controls had higher innate IL-1β 
levels7. We consider it likely that ex vivo cytokine production of lymphocytes is not fully 
independent of the disease status of the donor, however the fact that the observed 
association of the haplotype block to lower innate IL-1β bio-availability is observed mainly 
in subjects with lower ROA scores indicates that this association is not a result of bias 
introduced through OA severity. These findings are schematically represented in Figure 2. 
The LPS provoked immune reaction of the lymphocytes in OA affected subjects however, 
may be sensitized towards pro-inflammatory reactions as a result of the donors’ ongoing 
OA processes for example through upregulation of Toll-like receptors (TLR) on 
lymphocytes. To further substantiate the value of this finding, the associations need to be 
explored in a substantial cohort of healthy individuals. 
 
 
Figure 2. Schematic representation of the associations found within the GARP study sample with crude P-
values provided. It is shown that the association between the haplotype and the lower IL-1β availability is 
mainly due to the effect observed in the subjects that do not have OA at the highest number of joint locations (P 
value = 0.007) whereas the risk haplotype occurs more frequently among cases with the highest number of joint 
location with OA (P=0.003). The IL-1β availability in this patient group is, however, higher than expected both 
in the 2-2-1 haplotype group (0.78 as compared to 0.80, P = 0.066) and in the total group (0.80 as compared 
0.81, P =0.097). 
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4.2.2 Genome wide linkage search to identify putative regulatory genes in immune 
responses. 
As an example, the data discussed in Chapter 2.1 show that although associated to the 
innate IL-1β level, the genetic variation at IL1RN can not explain the full heritability 
component of this level, indicating that additional regulating genetic variation exists. In 
Chapter 2.2 we aimed to find additional genes influencing innate immunity of several 
innate cytokine levels by a genome wide linkage analysis of the GARP sibling pairs. For 
this analysis we used the assessed LPS stimulated profiles of cytokines (IL-1β, IL-1Ra, IL-
10 and TNFα) and data on microsatellite repeats across the genome. Confirmation of initial 
linkage signals ranging from 2.57 to 3.77 was done by combined linkage-association 
analysis of genetic variation within new candidate genes using the GARP data and 
replication was performed using the Leiden 85-Plus study, aiming to find genetic variation 
influencing innate immunity which was not only affecting OA subjects as present in the 
GARP study. We identified a SNP (rs6679497) in the CD53 gene which associated to 
innate TNFα levels (combined studies P-value < 0.01). The CD53 gene codes for a cell 
surface signaling protein, known to be expressed by lymphocytes and involved in the 
regulation of immune response. Previously, this protein was shown to be downregulated 
upon activation of neutrophils in response to activating stimuli by e.g. pro-inflammatory 
cytokines22 and CD53 deficiency has been linked to recurrent infectious diseases23. We 
tested whether the SNP was associated to OA in the GARP study as compared to the 
Leiden 85-Plus study subjects and to rheumatoid arthritis (RA) in a cohort of RA subjects 
with matched controls (personal communication, Prof. Dr. R. Toes et al., department of 
Rheumatology, LUMC) however no association to either disease was observed. It should be 
noted that the SNPs measured at CD53 tag 52% of the genetic variation recorded in the 
Hapmap database for this gene. Furthermore, innate TNFα was also not a major factor in 
OA onset as was shown by Riyazi et al. in the GARP study by comparing the GARP 
subjects to controls7. OA progression data in the subsequent studies in GARP subjects 
indicate a role for TNFα in progression of knee OA24, however no association to 
progression (at 2 years) was observed for the CD53 SNP either (personal communication, 
Dr. Kloppenburg et al., department of Rheumatology, LUMC). It should be noted that the 
number of progressing subjects in knee OA was small for genetic association analysis, 
thereby possibly giving false negative results. Other diseases and disorders, in which the 
TLR4 pathway that is mainly triggered through the LPS stimulation plays a prominent role 
might be affected by CD53 genotypic variation. In addition, no functional role for the 
identified SNP is known, and it is likely that this SNP is in partial LD to the true functional 
polymorphism, which might better show possible associations to OA or progression. 
Alternatively, we might have missed additional genetic variation on this locus of other 
genes as a result of a knowledge bias for known genes and their function. It is remarkable 
that in the linkage analysis we detected no linkage signals for innate IL-1β, IL-1Ra and IL-
10. Underlying to this may be the use of a patient population, where distribution of levels of 
at least innate IL-1β and IL-10 might be abnormal as compared to healthy controls, as 
indicated in Chapter 2.2. However, the use of Merlin-regress25, which deals with potentially 
skewed population traits, yielded similar results in our analyses. Most likely, the severe 
disease status of the most severely affected GARP subjects may have biased the innate 
response of the lymphocytes to the stimuli, thereby compromising the power and robustness 
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of the linkage analysis. Preferably, to identify putative regulatory loci of these possibly 
confounded levels healthy subjects should be used. 
 
4.2.3 Association analysis CRP genetic variation, serum CRP levels and OA 
In chapter 2.3 we explored the association of CRP haplotypes to the measured baseline 
serum HsCRP levels and to OA phenotypes in the GARP study. In the GARP study, 
Meulenbelt et al. showed that higher levels of HsCRP associated to increased BMI and 
knee OA26. Shortly after this publication a compelling study by Carlson et al. showed 
common haplotypes of the CRP gene associated to basal serum HsCRP levels in healthy 
individuals27. This publication triggered the obvious question whether these haplotypes 
underlie the association of HsCRP levels to OA as mentioned above. Upon determination 
of the CRP haplotypes in the GARP study the haplotypic pattern and its association to 
serum HsCRP was strikingly similar to the study by Carlson et al.27. Overall the HsCRP 
levels of the subjects of GARP study were not in the acute phase range and only subtle 
differences were observed between the haplotype mean levels. We could not find an 
association of any of these haplotypes to knee OA or BMI indicating that the previously 
observed associations are not likely causally related, but that the high CRP levels reflect 
ongoing processes of OA and/or high BMI. In the current data we cannot distinguish BMI 
driven effects on the serum HsCRP levels from effects mediated through knee OA because 
these are highly correlated features. However, haplotype 7/8(H7/8), which associated to 
higher serum CRP levels, associated to GARP subjects within the highest quartile of 
number of OA affected hand joints (frequency cases 0.096 whereas control frequency was 
0.046). The association of the CRP haplotype to both high serum HsCRP level and severe 
hand OA may indicate that H7/8 may causally contribute to OA etiology in hand joints. A 
lifelong exposure to subtle increased circulating CRP levels may have tipped the balance to 
pro-inflammatory responses upon damage, affected the integrity of the cartilage with age 
and ultimately leading to the onset of the OA process. It should be noted that the frequency 
of H7/8 was relatively low (frequency overall in the GARP study 0.06) and in the GARP 
study no direct association of serum HsCRP to hand OA was shown. The fact that we do 
not observe higher circulating serum HsCRP levels among subjects with hand OA might be 
attributable to the influence of confounding factors such as the effects of BMI and/or knee 
OA among subjects of the GARP study26, that easily affect the HsCRP levels and obscure 
possible OA subtype associations to circulatory levels. In a study of erosive hand OA 
patients Punzi et al. have shown increased levels of serum HsCRP28, however, this study 
has no genotype information available which could help to elucidate whether the haplotype 
association is observed in these subjects as well. In the GARP study 42 individuals scored 
positive for signs of erosive hand OA out of 260 individuals scored. In the GARP subjects, 
no association of the high serum HsCRP haplotype H7/8 was observed to the erosive hand 
OA phenotype (personal communication, Dr. Kloppenburg et al., department of 
Rheumatology, LUMC). Alternatively, serum HsCRP levels may act in OA through flares 
of disease activity, which can explain why we do not consistently observe increased serum 
HsCRP associations to hand OA in this cross sectional study design. It is remarkable that 
only the hand joints appear to be affected by the CRP haplotype in OA, the smaller joints of 
the hand might be more susceptible to subtle changes of circulatory serum levels of 
immunity signaling proteins, whereas the bigger joints have a more stable synovial level of 
inflammatory markers through a smaller surface to volume ratio. The reported associations 
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between the CRP haplotypes, levels and OA would benefit from confirmation in other 
larger study populations with severe hand OA as defined by ≥7 of 20 scored joint sites 
affected. 
 
4.2.4 Association analysis of SELS genetic variation, baseline inflammatory mediators 
and OA subtypes 
To further explore the role of circulating levels of inflammatory mediators we measured 17 
multiplexed cytokines and chemokines in plasma obtained from GARP subjects. 
Simultaneously, Curran et al. reported a promoter polymorphism -105 G/A of the SELS 
gene which was associated to higher levels of circulating pro-inflammatory cytokines29. In 
line with the working hypothesis this might increase susceptibility to OA. In addition to this 
promoter polymorphism, we genotyped 2 SNPs in the gene to increase the coverage of 
genetic variation present within the SELS gene. In this study we aimed to identify plasma 
markers of the ongoing OA process, as well as to characterize the subjects of GARP for 
possible predisposition to OA through genetic variation of the SELS gene. We observed no 
large scale up regulation of any of the measured cytokines and chemokines in relation to 
total ROA score or OA subtypes, indicating that none of the measured cytokines or 
chemokines is suitable as a marker for OA severity in the OA stages as present in the 
GARP study. The reported -105G/A promoter polymorphism association to higher 
circulating levels of IL-6, IL-1β and TNFα29 was not confirmed in the GARP study, nor 
could we detect any association between genetic variation at the SELS gene and OA. 
Since some of the 17 measured serum levels of cytokines and chemokines were highly 
correlated we performed a principal component analysis on 9 of these levels and included 
serum HsCRP levels in this analysis. We extracted 3 components representing 61.4% of the 
total variation in these markers. One haplotype (‘GAG’ frequency 0.04) of the SELS gene 
associated to 2 components, one of which depended mainly on serum IL-10 levels, whereas 
the other was mainly driven by serum HsCRP levels, indicating that genetic variation at 
SELS may indeed influence baseline inflammatory mediators. A third component which 
mainly represented variation of chemokines MIP-1β, MCP-1 and IL-8, was significantly 
associated to hand OA and disc degeneration. Contrary to expectation of increased pro-
inflammatory signaling, low levels of these chemokines captured in this component were 
associated to higher ROA scores. In the interpretation of this, it should be noted that 
subjects of the GARP study are selected on OA at multiple joint sites meaning that subjects 
with no hand OA had OA at other joint sites, however, we could not assess positive 
association between the chemokine levels and OA at other joint sites among GARP 
subjects. Previously, synovial chemokine levels were shown to be upregulated in OA 
affected joints as compared to controls30,31, our study shows that this up regulation might 
not be reflected in circulating serum levels, or this up regulation may be less pronounced in 
hand OA and disc degeneration as compared to hip OA and knee OA. Alternatively, the 
observed association is spurious, which calls for confirmation in other cohorts which have 
both data on hand OA and circulating chemokine levels available. Given the current results, 
it might be that the underlying pathophysiological processes of hand and spine OA as 
opposed to knee and hip OA are different, reflected in the associations found for the 
individual joint sites studied in the GARP subjects. 
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4.2.5 Inflammatory mediators’ levels and genes in OA 
In summary, our studies on mediators of inflammation and candidate genes in the 
inflammatory pathways, in addition to earlier publications on this subject, show that 
although significant associations were found between inflammatory mediators and OA, the 
underlying mechanism is highly complex and cannot be easily elucidated. The relation 
between cause and effect may be obscured once the process of cartilage damage is initiated 
and causal factors may inversely become markers of the ongoing disease processes. The 
identification of loci coding important immune modulating genes in healthy individuals 
may assist in the identification of cause and effect in OA research. Once the OA process is 
initiated a redundant cycle of cartilage damage and mainly catabolic activity in response to 
the damage may occur (Figure 1), which would be amplified through genetic predisposition 
towards pro-inflammatory states. The presence of these OA predisposing alleles may be a 
result of an advantageous effect in early development and life, where a fast chondrocyte 
cycle may be preferable in growth and repair of minor cartilage defects, however, may 
underlie OA onset and progression later in life after the reproductive phase.  
Individuals with OA in the GARP study show higher innate levels of IL-1β as compared to 
controls, however, the only observed genetic predisposition present in our data is to a low 
IL-1β bio-availability haplotype. This contrast illustrates the complexity of interactions of 
levels with disease status and predisposition through genetic variation reflected in levels. 
We aimed to find additional candidate genes for association analysis to OA and by a 
genome wide linkage scan we identified a CD53 SNP which associated to innate TNFα 
levels, however, we were unable to detect association of this SNP to either OA or RA. The 
estimates of the innate immunity were obtained through a stimulation using LPS which acts 
on the Toll-like receptor 4 (TLR4). It can be argued that for a better or more complete 
overview of innate immunity in relation to osteoarthritis stimulation through the TLR2 
pathway may provide additional information. Both TLR pathways are implicated in 
autoimmunity, however, TLR4 is more intimately involved in the pathogen response 
whereas TLR2 is more involved in allergies and autoimmunity protection. In addition to 
innate immunity estimates, we investigated circulating levels of immune signaling proteins 
aiming to identify mediators or markers of the disease process. We showed that a CRP 
haplotype H7/8 associated to high serum HsCRP levels as well as to OA at multiple sites of 
the hand. In this case we were not able to show higher serum HsCRP levels for individuals 
of GARP who had OA of the hand as compared to subjects without involvement of the 
hand, nor did we find evidence for association of this haplotype to erosive hand OA, which 
is reported to associate to higher serum HsCRP levels. In this respect, confounding by other 
joint sites and traits might obscure possible associations of serum HsCRP levels to OA, as 
is shown especially in the case of knee OA which is confounded by the correlation of BMI 
and knee OA26. We were unable to show any relation between SELS haplotypes associated 
to specific inflammatory components and features of OA. By use of prospective or early 
OA cohorts, such as the Cohort Hip and Cohort Knee (CHECK) study, which is currently at 
a 10 year follow up of a thousand subjects with early clinical signs putatively caused by 
OA, the causal role of levels of inflammatory mediators in the onset of OA might be better 
studied since the disease status may not yet evoke a strong reaction of these inflammatory 
system. 
Altogether, our investigation of patterns between genetic variation of markers, the levels of 
the markers and disease status has not revealed a clear relationship between inflammatory 
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mediators, genetic variation and OA. None of the associations found for genetic or 
circulatory levels was present in all subjects of the GARP study, underlining that OA is a 
multifactorial disorder, in which several aspects influence the disease onset and 
progression. Identifying each of the associating genetic and circulating factors might 
together comprise a risk profile for OA and can help to better identify early OA and provide 
patient prognosis. For better pattern recognition analyses may benefit from an approach 
using the Mendelian randomization model6. In this approach, a sufficiently large sample of 
healthy individuals is used to identify which genetic variants influence which levels. 
Subsequently, these patterns can be investigated in diseased cohorts to identify possible 
associations of variants to the disease, or whether levels are confounded by the disease 
process itself. In particular for diseases in which the marker levels may not be independent 
from the disease status this approach may be very beneficial. Furthermore, the OA process 
mainly acts in the synovial compartment, which may not necessarily be reflected in the 
circulating levels of inflammatory mediators. More insights in the relation between 
circulating levels of inflammatory mediators and local signaling in the joints are needed to 
reliably identify putative disease monitoring markers. In addition, our analyses were aimed 
at specific inflammatory mediators, whereas the immune system is highly complex with 
more factors involved. In our analysis we may have omitted markers which are intimately 
involved in the disease process, however, not identified as OA markers. 
 
4.3 Developmental characteristics of OA 
In addition to genes of the inflammatory pathway, recent candidate gene studies and 
genome wide linkage and association scans indicate that genes which act during the early 
stages of osteogenesis and chondrogenesis should be considered as regulators of an 
important pathway in the etiology of OA1,3,32,33(see Chapter 1 for a complete overview). 
Variants of developmental genes may affect joint morphology of the bone during early 
development, where subtle changes in shape might create a lifelong exposure to aberrant 
joint loading, ultimately wearing out the cartilage and initiating OA. Currently, in 
collaboration with the Erasmus University of Rotterdam (Prof. Dr. H. Weinans and Dr. J.H. 
Waarsing et al. department of Orthopedics, Erasmus MC), the shape of hips is being 
characterized using statistical shape models. These can subsequently be used to identify 
putative predisposing shape aspects, as well as identify whether genes influence the shape 
of joints, possibly contributing to the OA etiology through these shape aspects. Secondly, 
loss of maturational arrest in articular chondrocytes and initiation of chondrocyte 
hypertrophy might be one of the events which set off a cycle of processes where the 
chondrocytes follow a path resembling that observed in the growth plate which is 
debilitating for the articular cartilage21,34,35. Genetic variation at the genes which regulate 
these processes might exert their effects later in life when the cartilage matrix ages and age 
related expression changes in cells occur36-38. DIO2 is one of the genes which is active in 
the growth plate during endochondral ossification, and was identified in the GARP study as 
candidate OA susceptibility gene and confirmed by several additional OA cohorts5. DIO2 
codes for type II deiodinase (D2) which regulates the availability of active thyroid hormone 
T3 in the growth plate during endochondral ossification
39. Active T3 signals in the growth 
plate direct the chondrocytes towards terminal differentiation, eventually resulting in the 
formation of bone. Recent findings using mouse models show the reactivation of 
endochondral ossification genes in a mouse model of mechanically induced OA, supporting 
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the possibility that reactivation of these genes plays a role in OA etiology35,40. In addition to 
these data, chondrocytes from aged donors are less responsive to anabolic signaling and 
have decreased mitotic ability, thereby increasing the susceptibility to OA onset41,42. In the 
growth plate, developmental genes are known to regulate the ongoing process of 
endochondral ossification; the breakdown of cartilage and formation of bone. These 
features are also major characteristics of the ongoing OA process. This hypothesis was 
recently reviewed by us, where DIO2, GDF5 and FRZB in particular were discussed1. In 
this thesis we performed two studies further characterizing D2 in OA cartilage as compared 
to healthy cartilage and characterizing the DIO2 risk allele of rs225014 in OA cartilage. 
These studies can be considered the first efforts to follow up a gene identified through a 
genome wide approach in OA. Depending on the genes and polymorphisms identified in 
several ongoing genome wide association studies and meta analyses of these, a similar path 
of follow up experiments can be expected to further investigate the involvement in OA 
etiology of these and other discovered OA susceptibility genes. 
In Chapter 3 we showed that the OA risk allele of DIO2 SNP rs225014 is more abundantly 
transcribed in OA cartilage at the mRNA level as compared to the reference allele. Though 
a higher rate of transcription of the risk allele a subtle imbalance of D2 protein production 
may be present which in turn activates more thyroid hormone T3 during life. The fact that 
this SNP resides in an exon, which generally do not harbor the majority of the regulatory 
elements of genes, may indicate that this SNP is merely a marker for variation in cis-acting 
regulatory elements such as putative methylation sites or promoter variation which form the 
true underlying cause. Moreover, it should be noted that the polymorphism is very close to 
a CTCF binding site, which are known to be involved in gene activity regulation through 
DNA methylation, possibly, the methylation status of this site is altered under the influence 
of the OA risk allele. The identified risk SNP rs225014 codes for an amino acid change in 
the D2 protein, however, no conclusive evidence is found that this amino acid change has 
major effects on the enzyme efficacy and stability43. The absence of changes in enzyme 
activity or stability44 further points towards a regulatory cis-acting element underlying the 
observed association. 
Furthermore, in the IHC analyses the observation that in OA cartilage as compared to non 
OA cartilage D2 is both more abundantly expressed throughout all the cartilage layers as 
well as at higher staining intensity, together with similar pattern of expression differences 
of the thyroid hormone receptor beta and DIO3 indicates that in OA cartilage increased 
thyroid signaling is present. Possibly, the OA risk allele may contribute to this higher 
expression of D2 through the described allelic imbalance. Overall, it is unclear whether age 
related dedifferentiation of the chondrocytes contribute to the observed increase in 
expression of thyroid signaling proteins or whether the differences observed in expression 
level is merely a marker of the ongoing disease process. To overcome this a study cohort 
which allows investigation of the influence of aging on the expression of these proteins in 
healthy cartilage is needed. 
 
4.4 Future perspectives 
Recently, candidate gene and genome wide approaches have shown consistent associations 
for several genes in osteoarthritis. In a follow up of these initial findings, these genes now 
need to be characterized in relevant tissues and through in vitro and in vivo models in order 
to further elucidate the mechanisms behind the associations. In designing new experiments, 
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researchers should take into consideration that focus should be on identifying common 
genetic variation which cumulatively add up to a composite risk for OA development, as 
well as on the identification of rare, large effect genetic variation which has in itself a 
stronger effect on the OA predisposition. International collaborative GWAS and linkage 
approaches significantly increase the power of studies into OA, however, also bring about a 
new challenge regarding the phenotypic heterogeneity of the combined cohorts. In order to 
cope with these challenges, additional research will be needed to further homogenize the 
OA phenotyping of already assessed cohorts and new OA research initiatives. Through 
collaborations researchers in the genetics of OA may lay down a path towards new 
therapeutic approaches for disease modification and treatment45. Once genetic variation 
contributing to OA is identified, the research enters a new phase of characterizing the 
specific variation identified. Through promoter activity assays, sequencing, animal models, 
expression analysis and many other emerging genomics and proteomics techniques a more 
detailed insight can be gained, where each specific gene may have an obvious next step to 
take. One of these arising genomics fields allows high throughput assessment of epigenetic 
configuration of genes as determined by methylation status. Especially in silencing of e.g. 
developmental and catabolic genes, methylation is a potent genetic regulatory mechanism, 
which may play a role in OA etiology. Use of DNA extracted from OA and healthy joints 
can readily test hypothesis regarding methylation of specific genetic areas and is currently 
ongoing. Furthermore, as no functional roles for the DIO2 OA risk polymorphisms are 
identified we aim to use high throughput sequencing techniques to find putative new rare 
variants with large impact, which may give us more insight in the molecular mechanisms 
behind the associations. The possible link between the processes of the endochondral 
ossification and osteoarthritis calls for a new range of experiments where this link can be 
further characterized. By challenging cartilage explants of donors of different ages with 
signaling similar to that found in the growth plate during endochondral ossification we may 
better understand the observed similarities between OA and endochondral ossification and 
the relation of the disease to aging. Characterizing the differentiation processes of 
mesenchymal stem cells or pluripotent cells derived from (more easily obtainable) 
fibroblasts using donors of different genotypes under similar conditions may tell us more 
about why associations of these alleles occur. Furthermore, allelic imbalance of transcripts 
may be mediated through copy number variation, which is one of the advantages in the next 
generation sequencing techniques, which are highly reliable in identifying copy number 
variations. Further experiments using healthy cartilage to determine the reported rs225014 
allelic imbalance might show whether in OA cartilage aberrant signaling as compared to 
healthy samples occurs at the level of ongoing thyroid signaling. Such differences might 
indicate presence of transcription factors not normally active in the cartilage, or differential 
epigenetic regulation of cis-regulatory elements in OA etiology. 
Ultimately, new techniques and insights will allow better distinction of ongoing disease 
processes, thereby creating more understanding of the origin of the observed disease 
heterogeneity. Osteoarthritis may be the end stage of several distinct pathways; through 
identification of markers reflecting the ongoing processes possibly these pathways are 
better understood, monitored and targeted. Furthermore, to provide clinicians with effective 
disease modifying drugs, these experiments may unravel the complex mechanisms 
involved, thereby identifying potent drugable targets in OA. 
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Summary 
 
We have investigated associations of levels of inflammatory mediators, genetic variation 
and features of osteoarthritis (OA). A summary of our findings is provided in Table 1. 
Overall, we were only able to find fitting associations for the CRP gene. We identified a 
haplotype of the CRP gene which associated to higher circulating levels of serum HsCRP 
as well as to increased numbers of affected joints of the hand in the GARP study (Chapter 
2.3), which follows the generally accepted hypothesis that a high inflammatory status is 
detrimental to the cartilage. The association is most likely reflecting a causal relation 
between high basal CRP levels and the onset of hand OA. It is contradictory that in spite of 
the identified association the levels of the GARP subjects with high amounts of hand OA 
are not different from the other GARP participants, possibly due to the fact that all 
participants in this study are affected by OA at multiple joint sites. 
A more complex association and interaction described in this thesis regards the haplotypes 
of the IL-1 gene cluster which previously were shown to be associated with the innate 
levels of cytokines and OA features thereby verifying the generally accepted hypothesis 
that high innate IL-1β production capacity is detrimental to the cartilage. However, as 
described in this thesis we identified a haplotype associated to innate lower IL-1β bio-
availability which was also associated to subjects with the highest overall ROA scores, 
indicative of more complex mechanisms underlying the associations found (Chapter 2.1). 
Furthermore, for the SELS gene we found evidence for a role of Selenoprotein S genetic 
variation in the circulating levels of components representing pro- and anti-inflammatory 
signaling in GARP subjects. In spite of these associations to cytokine levels we were unable 
to show that these genetic variations associated to OA features, whereas we did observe 
association of a third component mainly representing chemokine variation to features of 
hand OA and degeneration of the spinal discs (Chapter 2.4). 
In these analyses for each answer found, we raised new questions towards the role of 
genetic variation of genes encoding regulators of the immune system. In search of new loci 
associated to innate immunity and thereby possibly involved in OA etiology, we showed 
the association of CD53 to innate TNF alpha levels, however, the innate levels of TNF 
alpha appear to have no substantial role in OA etiology. As we expected based on this 
knowledge, the CD53 genetic variation which was associated to TNF alpha did not show 
associations to OA or any subtypes thereof (Chapter 2.2). 
 
Table 1. Summary of associations between genetic variation, inflammatory mediators and OA. 
 Associations 
Gene Haplotypes to levels Haplotypes to OA Levels to OA 
CRP Yes (Serum HsCRP) Yes (Hand ROA) No 
IL-1 gene cluster Yes (Innate IL-1β bio-availability) Yes (ROA) Yes (Innate IL-1β bio-availability)* 
SELS Yes (Cytokines and serum HsCRP) No Yes (Chemokines) 
* Innate IL-1β bio-availability hold an inverse relation for haplotype association and levels association to OA, i.e. the 
associated haplotype mediates lower Innate IL-1β bio-availability whereas the associated levels appears to be high innate 
IL-1β bio-availability 
 
Aided by the various genetic findings in the OA research, including larger genome wide 
approaches, the developing view in the OA research field is that in addition to the long 
investigated inflammatory genes there is mounting evidence that genetic variation at genes 
involved in the processes of skeletal development and maintenance, and the endochondral 
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ossification in particular may contribute to the heritabile component of OA. The 
identification of DIO2 genetic variation which associated to OA in a large, multicenter and 
multiethnic study triggered us to investigate the coding polymorphism rs225014. By use of 
a differential allelic expression assay we showed that the risk allele is transcribed at a 
higher rate in the affected cartilage of heterozygous carriers of this polymorphism (Chapter 
3). This leads us to hypothesize that a cis acting regulatory element, such as a differential 
methylation or promoter polymorphism may underlie the DIO2 association to OA. These 
data are corroborated by the immunohistochemical analyses of OA and non OA cartilage, 
where we show higher protein presence of DIO2’s gene product type II deiodinase (D2), as 
well as for the other thyroid signaling related proteins type III deiodinase and thyroid 
receptor beta (Chapter 3). Through a higher protein presence of D2 which may be at least in 
part caused by the higher activity of the risk polymorphism, the inactive thyroid hormone 
T4 is converted to active thyroid hormone T3. During the endochondral ossification, D2 
activity increases T3 levels in the growth plate, and this hormone triggers the chondrocytes 
to enter their terminal differentiation, ultimately forming the bone and facilitating the 
longitudinal growth of bones. This process has a striking resemblance to the processes 
observed in the articular cartilage where the chondrocytes display similar features. Through 
the identification of DIO2 genetic variation associated to OA, we may have found 
additional proof that a loosening of the maturational arrest of chondrocytes during life may 
be lost, ultimately leading to the loss of articular cartilage and formation of osteophytes. 

Nederlandse samenvatting 
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 6.1 Introductie 
Artrose is de meest voorkomende aandoening van het bewegingsapparaat. Het proces wordt 
gekenmerkt door de afbraak van het kraakbeen op de gewrichtsdelen en de vorming van bot 
op de randen van de gewrichten (osteofyten). Op röntgenfoto’s zijn deze 2 kenmerken 
zichtbaar als een vernauwing van de gewrichtsspleet en verbreding van de 
gewrichtsoppervlakten. Klinische symptomen van artrose zijn pijn in de gewrichten en 
beperking van de bewegingsvrijheid. De meest voorkomende aangedane gewrichten zijn de 
handen, knieën, heupen en wervelkolom. De oorzaak van de ziekte is nog grotendeels 
onbekend, hoewel duidelijk is dat de balans van aanmaak en afbraak van de componenten 
van het kraakbeen verstoord is. 
Artrose heeft een grote erfelijke component, wat verklaard waarom de ziekte vaak in 
families voorkomt. Naast de erfelijke component spelen ook andere factoren zoals leeftijd, 
geslacht, overgewicht en beroep een rol wat het onderzoeken van de erfelijke component 
moeilijker maakt. De recente bevindingen die door genetisch onderzoek zijn gedaan duiden 
erop dat in het ontstaan van artrose twee processen een grote rol spelen. Het eerste proces is 
het ontstekingsmechanisme en het tweede proces is de endochondrale verbening die 
plaatsvindt tijdens de lengtegroei van botten en formatie van gewrichten. 
 
6.2 Kraakbeen en onderzoeksdoelen 
Het kraakbeen wordt gevormd gedurende de ontwikkeling van de gewrichten. Het ontstaat 
uit een groep gespecialiseerde cellen die tijdens de vorming van de botten als kraakbeen 
cellen een matrix om zich heen leggen die het articulaire kraakbeen genoemd wordt. 
Eenmaal gevormd blijft het kraakbeen levenslang haar functie van soepele beweging en 
demping van schokken verrichten. De kraakbeencellen zijn maar spaarzaam aanwezig in 
het kraakbeen, delen zich niet en hun activiteit is heel laag (Zie ook Hoofdstuk 1 blz. 12, 
Figuur 2A). Gedurende het leven gaan kleine hoeveelheden van de bouwstenen van het 
kraakbeen kapot en de kraakbeencellen zijn net actief genoeg om dit op te ruimen en weer 
aan te vullen. Dit proces is zorgvuldig gebalanceerd, onder andere doordat de kraakbeen 
cellen gevoelig zijn voor ontstekingsparameters die onder invloed van schade aan het 
kraakbeen vrijkomen. Het is bekend dat teveel van deze ontstekingparameters deze balans 
van opbouw en afbraak kunnen verstoren, waardoor teveel kraakbeen verloren gaat. Een 
van de algemeen aanvaarde hypothesen in artrose is dat deze balans verstoord is in de 
richting van de afbraak van het kraakbeen. In dit proefschrift hebben wij voor meerdere 
ontstekingsparameters onderzocht of we deze hypothese konden bevestigen. Daarnaast zijn 
in de recente wereldwijde onderzoeken naar artrose genen gevonden die coderen voor 
eiwitten die in de vroege ontwikkeling van bot en kraakbeen een rol hebben. Een van 
dergelijke genen, die door ons werd geïdentificeerd is het DIO2. Verder onderzoek moet nu 
uitwijzen wat mogelijke achterliggende oorzaken zijn voor de betrokkenheid van dit gen bij 
artrose. We onderzochten mogelijke verschillen in de snelheid van het afschrijven van 
varianten van dit gen. Daarnaast werd onderzocht of het eiwit waar DIO2 voor codeert, 
samen met enkele aanverwante eiwitten daadwerkelijk aanwezig is in kraakbeen met en 
zonder artrose. 
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6.3 Studie populaties 
Om te onderzoeken welke processen een rol spelen in artrose zijn in dit proefschrift 
verschillende studies gebruikt, waarvan de GARP (Genetica ARtrose en Progressie) en 
RAAK (Research Artrose en Articulair Kraakbeen) de belangrijkste twee zijn. 
De GARP studie, een samenwerking met de afdeling Reumatologie, bestaat uit een grote 
groep van broer- en/of zus-paren tussen de 40 en 70 jaar met klinische klachten en 
radiologisch aangetoonde artrose in twee of meer gewrichtsgroepen (hand, heup, knie en 
wervelkolom). Van deze patiënten hebben wij ook DNA, RNA, bloed en urine afgenomen 
zodat we relevante metingen kunnen doen. In het kader van dit proefschrift hebben we 
vooral ontstekingsparameters gemeten en deze, met relevante genen voor deze parameters 
in associatiestudies* met artrose onderzocht. Daarnaast is in de GARP studie met behulp 
van een koppelingsonderzoek** gezocht naar nieuwe varianten van genen die de maximale 
productiecapaciteit van bloedcellen voor ontstekingsparameters beïnvloeden. 
De RAAK studie is een lopende samenwerking met afdeling Orthopedie in het Leids 
Universitair Medisch Centrum in Leiden en het Rijnland Ziekenhuis in Leiderdorp waarbij 
de chirurgen bij operaties van patiënten die een gewrichtsvervanging nodig hebben het 
verwijderde gewrichtsmateriaal voor onderzoek insturen. In dit materiaal kunnen we 
onderzoek doen in de voor artrose meest relevante weefsels zoals kraakbeen, bot en de 
ligamenten. 
 
*Associatiestudies vergelijken twee groepen personen, waarvan één groep aangedaan is 
met de ziekte, en de andere groep de ‘normale’ bevolking representeert. Voor een 
kandidaatgen, dat ervan verdacht wordt een rol te spelen bij de ziekte kan worden bekeken 
of varianten van dit gen vaker voorkomen bij de patiënten dan bij de controle personen; er 
is dan sprake van associatie van een variant met de ziekte. De oorzaak van deze associatie 
kan dan liggen in een eigenschap van deze variant zelf, of een variant die hier dichtbij ligt 
op dezelfde DNA streng. Bij het overerven van het DNA worden grote stukken met hierop 
meerdere varianten vaak geheel overgedragen van ouder op kind. Zo’n stuk DNA heet een 
haplotype, en in dit proefschrift is voor meerdere genen onderzoek gedaan naar dergelijke 
haplotypen. Wij onderzochten niet alleen of haplotypen van genen vaker bij aangedane 
personen te vinden waren, maar ook of deze haplotypen bloedwaarden van relevante 
ontstekingsparameters beïnvloeden. 
**Koppelingsstudies maken gebruik van het gelijktijdig overerven van grote stukken DNA 
binnen families waarin een ziekte vaker voorkomt. Broers en zussen delen onderling 
gemiddeld 50% van hun DNA, de overige 50% is verschillend. Door in kaart te brengen 
welke delen van het DNA gedeeld worden en welke delen uniek zijn, kunnen we bij 
aangedane familieleden nagaan op welke 50% van het DNA de genen liggen die betrokken 
zijn bij het ontstaan van de ziekte. Door het verzamelen van heel veel van dit soort paren 
uit verschillende families is het mogelijk om nauwkeurig vast te stellen welk deel van het 
DNA door al deze paren vaker gedeeld wordt dan wat op basis van toeval verwacht wordt. 
Door deze ‘koppeling’ van ziekte aan een stukje van het DNA kunnen we in dit stukje DNA 
verder zoeken naar de mogelijke genvarianten die het risico op de ziekte verhogen. In dit 
proefschrift gebruikten wij deze aanpak om binnen een groep broer-zus paren te 
onderzoeken welke gebieden op het DNA genen kunnen bevatten die de bloedwaarden van 
relevante ontstekingsparameters kunnen beïnvloeden. 
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6.4 Interleukine-1 gen cluster onderzoek 
Interleukine-1 is een sterk pro-inflammatoire ontstekingsparameter, die de kraakbeencellen 
kan aanzetten tot de productie van enzymen die de kraakbeen matrix afbreken (Zie ook 
Hoofdstuk 4 blz. 108, Figuur 1). Door bloedcellen te stimuleren met een stof die lijkt op 
een bacterie produceren deze bloedcellen op maximale snelheid ontstekingsparameters, 
zoals de verschillende vormen van het interleukine(IL)-1. In bloed van de GARP patiënten 
hebben we onderzocht of de genen die coderen voor IL-1 (IL1RN, IL1A en IL1B) associëren 
met de maximale capaciteit van bloedcellen om IL-1 bèta en IL-1 receptor antagonist(Ra) te 
produceren. We vonden dat een haplotype van het IL1RN gen associeert met de biologische 
beschikbaarheid van IL-1 bèta (de verhouding tussen IL-1 bèta en de IL-1 receptor 
antagonist). Dragers van dit haplotype hebben een lagere biologische beschikbaarheid van 
IL-1 bèta, maar meer radiologische handartrose. Gegeven dat pro-inflammatoire signalen 
het kraakbeen aanzetten tot productie van afbraakenzymen, verwachtte wij bij een lage 
biologische beschikbaarheid van IL-1 bèta juist minder aanleg voor artrose. Een mogelijke 
verklaring voor onze bevinding is dat gedurende het leven het kraakbeen onderhouden 
wordt door een balans tussen de pro- en anti-inflammatoire eiwitten, waarbij bij kleine 
beschadigingen mogelijk een voldoende sterke actie van IL-1 bèta nodig hebben om de 
reparatie op gang te krijgen, of de kleine schade voldoende op te ruimen voordat de 
reparatie van de kraakbeenmatrix kan plaatsvinden. 
 
6.5 Koppelings analyse met maximale productiecapaciteit van ontstekingsparameters 
De genetische variatie waarvan bekend is dat het ontstekingsparameters beïnvloed verklaart 
niet de volledige erfelijkheid hiervan. Met behulp van een genoom wijde koppelings 
analyse in de GARP studie zochten we naar genen die ook aan de genetische component 
van deze bloedwaarden bijdragen. In deze analyse ontdekten wij een variant in het CD53 
gen, die associeert met de maximale productie capaciteit van bloedcellen voor tumor 
necrose factor (TNF) alpha, een sterk pro-inflammatoir eiwit. Uit eerdere onderzoeken 
blijkt dat maximale capaciteit van de bloedcellen om TNF alpha te produceren niet 
geassocieerd is met de aanwezigheid van artrose, en deze genetische variant heeft dan ook 
geen relatie met het ontstaan van artrose in de GARP studie. Mogelijk is de door ons 
geïdentificeerde variant wel van belang bij andere aandoeningen waarbij de maximale TNF 
productiecapaciteit van de bloedcellen wel een grote factor is bij het ontstaan of voortgang 
van de aandoening, een hypothese die nader onderzocht moet worden. 
 
6.6 CRP haplotypen, CRP levels en artrose 
CRP is een eiwit wat een breed scala aan processen reguleert en sterk pro-inflammatoire 
ontstekingsparameters aanzet. Een eerder onderzoek wees uit dat genetische variatie in het 
CRP gen de basale bloedwaarden van dit eiwit beïnvloed. Wij onderzochten of wij deze 
relatie van gen en bloedwaarden in de GARP studie konden bevestigen, en of de genetische 
variatie mogelijk een invloed heeft op de mate van artrose. Het haplotype 7/8 van dit gen, 
wat geassocieerd is met hoge bloedwaarden voor het CRP associeert ook met ernstige 
handartrose (gedefinieerd als 7 of meer aangedane gewrichten van 20 gescoorde 
gewrichten). Dit zou kunnen duiden op een relatie tussen de hoge CRP waarden onder 
invloed van dit haplotype en de ernstige schade aan het kraakbeen van de handen. De 
bloedwaarden van de mensen die ernstige handartrose hebben zijn echter niet hoger in 
Nederlandse samenvatting 132 
vergelijking met de rest van de GARP studie. Dit mogelijk is te wijten aan het feit dat alle 
deelnemers in de GARP studie artrose op meerdere gewrichtslocaties hebben. 
 
6.7 Selenoprotein S gen variatie, ontstekingsparameters en artrose 
In een associatie studie, uitgevoerd door een buitenlandse onderzoeksgroep werd 
aangetoond dat het selenoprotein S gen (SELS) associeert met bloedwaarden van IL-6 , IL-1 
bèta en TNF. In de GARP studie onderzochten wij of we deze relatie konden verifiëren in 
onze artrose patiënten. Hoewel de gerapporteerde associatie niet werd gereproduceerd was 
de genetische variatie in het gen wel met verschillende cytokines geassocieerd, wat duidt op 
een rol van dit gen in de bloedwaarden van ontstekingsparameters. De genetische variatie in 
het gen associeerde echter niet met artrose wat erop duidt dat de rol van dit gen niet direct 
met artrose heeft te maken. 
 
6.8 Samenvatting ontstekingsparameters en artrose 
In Tabel 1 geven we de gevonden relaties tussen genen, ontstekingsparameters en artrose 
weer welke in dit proefschrift beschreven zijn. 
 
Tabel 1. Samenvatting van gevonden relaties tussen genen en ontstekingsparameters in artrose 
 Associaties 
Gen Haplotype met bloedwaarden Haplotypen met artrose Bloedwaarden met artrose 
CRP Ja (Serum HsCRP) Ja (Hand ROA) Nee 
IL-1 gen cluster Ja (Max. biol. beschik. IL-1β) Ja (ROA) Ja (Max. biol. beschik. IL-1β)* 
SELS Ja (Cytokines en serum HsCRP) Nee Ja (Chemokines) 
* De biologische beschikbaarheid van IL-1 bèta heeft een tegengestelde relatie voor de haplotype associatie en 
bloedwaarden associatie met artrose; het haplotype wat associeert geeft lage bloedwaarden, waar de bloedwaarden die met 
artrose associëren juist de hogere waarden zijn. 
Max. biol. beschik. IL-1β staat voor de maximale biologische beschikbaarheid van IL-1 bèta, ROA staat voor radiologisch 
bepaalde artrose. 
 
Samenvattend kunnen we stellen dat artrose en ontstekingsparameters een intieme relatie 
hebben waarbij het moeilijk is om de oorzaak en gevolg te onderscheiden. De met artrose 
gepaard gaande afbraakprocessen van het kraakbeen zorgen mogelijk voor een subtiele 
verhoging van de bloedwaarden van de patiënten waardoor het moeilijk is om te 
achterhalen of de genen die met artrose associëren zorgen voor deze hoge waarden, of juist 
de bloedwaarden hoog zijn als het gevolg van het artroseproces. Het opstellen van studies 
van gezonde personen of personen met vroege artrose zou een goede stap zijn om deze 
relatie nader te onderzoeken. Zulke onderzoeken kunnen op verschillende tijdspunten de 
relatie tussen het ontstaan van artrose en bloedwaarden van ontstekingsparameters 
waarnemen en hierdoor een richting aan de associaties geven die worden waargenomen. 
 
6.9 Karakterisatie van het DIO2 gen in artrotisch kraakbeen 
In de GARP studie toonde een eerder onderzoek van onze groep aan dat de rs225014 T>C 
variant in het gen DIO2 het risico op het krijgen van artrose verhoogt. DIO2 codeert voor 
type II deiodinase(D2), een eiwit wat inactief thyroid hormoon T4 omzet in actief thyroid 
hormoon T3. Tijdens de lengtegroei van botten en de formatie van gewrichten 
(endochondrale verbening) is D2 en daarmee actief T3 aanwezig wat signaal geeft aan de 
chondrocyten in de richting van terminale differentiatie en de uiteindelijke formatie van bot 
stimuleert. 
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In de RAAK studie is artrotisch kraakbeen van patiënten verzameld, en in deze studie zijn 
de kraakbeen biopten van personen die zowel een risicovariant als een normale variant van 
rs225014 dragen onderzocht om mogelijke verschillen in de genactiviteit te onderzoeken. 
We hebben met dit onderzoek aangetoond dat de risico variant een veel hogere genactiviteit 
geeft in vergelijking met de normale variant van het gen. Een dergelijk verschil in activiteit 
kan worden veroorzaakt doordat de regulatie van de twee varianten verschilt. Dit verschil in 
activiteit duidt aan dat dit mogelijk onderliggend is aan het hogere risico op het ontstaan 
van artrose in personen die drager zijn van de C-variant. 
In samenwerking met de afdeling Pathologie van het LUMC hebben we ook artrotisch en 
niet artrotisch kraakbeen materiaal microscopisch onderzocht voor de aanwezigheid van het 
DIO2 genproduct D2, evenals aanverwante eiwitten type III deiodinase en de thyroid 
hormoon receptor bèta. In het kraakbeen van artrosepatiënten werd met toenemende mate 
van kraakbeenschade een hogere activiteit van deze eiwitten waargenomen, in vergelijking 
met de niet artrotische coupes. De hogere aanwezigheid van het eiwit duidt op meer 
activiteit van de thyroid hormoon as, wat de overgang van de chondrocyten naar de 
terminale differentiatie zal bevorderen. Deze terminale differentiatie zal de 
kraakbeenkwaliteit verslechteren en nog verder doen afbreken. 
 
6.10 Conclusie 
Het onderzoek naar artrose krijgt, onder invloed van de wereldwijde vergrijzing en 
gepaarde toename van de gevolgen van deze aandoening onder de bevolking meer en meer 
aandacht. In dit proefschrift hebben we de rol van ontstekingsparameters en de genen die 
deze reguleren in artrose onderzocht. De complexiteit van de communicatie over en weer 
tussen de genen, ontstekingsparameters en artrose ontstaat doordat de ziekteactiviteit ook 
de ontstekingsparameters beïnvloed. We toonden aan dat een haplotype van het CRP gen 
dat codeert voor hogere CRP bloedwaarden bij handartrose betrokken is. Daarnaast 
identificeerden we een component van chemokines die ook invloed heeft op de mate van 
handartrose in de GARP studie, de richting van deze laatste associatie anders is dan 
verwacht, wat de complexiteit van de rol van ontstekingsparameters in artrose onderstreept 
of een gevolg is van de manier waarop de GARP studie verzameld is. Een nog 
ingewikkeldere associatie vonden wij voor de rol van de maximale biologische 
beschikbaarheid van IL-1 bèta in artrose. Een haplotype dat associeert met lage biologische 
beschikbaarheid geeft meer handartrose, mogelijk door onvoldoende activatie van matrix 
reparatiemechanismen of opruiming van de beschadigde matrix bij kleinere schades aan het 
kraakbeen. Naast de ontstekingsparameters komen de genen betrokken bij de ontwikkeling 
van bot en gewrichten meer en meer onder aandacht als gevolg van bevindingen in het 
genetische onderzoek. Deze genen kunnen zowel vroeg in het leven, bij de ontwikkeling en 
vorming van gewrichten als later in het leven, bij het onderhoud van het articulaire 
kraakbeen een rol spelen. Subtiele verschillen in gewrichtsvorm of botsamenstelling 
vergroten mogelijk het risico op artrose door lokaal grotere stress op het kraakbeen bij 
normaal gebruik. De genen die actief zijn in de groeiplaat gedurende de lengtegroei zijn in 
het gezonde articulaire kraakbeen niet actief, maar mogelijk wordt met het ouder worden 
deze onderdrukking van activiteit verloren onder de invloed van activiteit van genen zoals 
DIO2. Het onderzoek beschreven in dit proefschrift toont aan dat de genetische variatie die 
associeert met artrose een grotere genactiviteit zou kunnen veroorzaken in kraakbeen. 
Daarnaast werd tussen gezond kraakbeen en artrotisch kraakbeen een verhoging van de 
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aanwezigheid van dit eiwit waargenomen, wat de hypothese van verhoging van de 
genactiviteit en daarmee gepaard gaande afbraak van het kraakbeen ondersteunt. 
Toekomstige genetische bevindingen kunnen op soortgelijke wijze op functionele activiteit 
getoetst worden, waarbij de nieuwe technieken zoals sequencing en DNA-methylatie 
metingen kunnen bijdragen aan respectievelijk de identificatie van nieuwe functionele 
varianten en bepaling van de achterliggende oorzaak achter toegenomen genactiviteit. 
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De totstandkoming van dit proefschrift is de resultante van het samenwerken van vele 
handen en geesten. Allereerst ben ik veel dank verschuldigd aan de deelnemers van onze 
verschillende studies, waarbij de GARP studie en RAAK studie specifiek genoemd moeten 
worden. Zonder de medewerking van de patiënten zou het onderzoek nooit van de grond 
komen, laat staan dat we steeds meer te weten komen over de ziekte artrose en de 
achterliggende mechanismen hierin. De onderzoekers en medewerkers van de verschillende 
afdelingen van het LUMC en Rijnland ziekenhuis in Leiderdorp hebben hierin ook 
substantieel veel bijgedragen. Met name de gedreven onderzoekers van de reumatologie, 
orthopedie, pathologie en ouderengeneeskunde zijn een fijne groep mensen waarmee het 
samenwerken in het opzetten en de verzameling van biobanken als vanzelf gaat. Deze 
collega’s komt veel lof toe in hun gedrevenheid en nauwkeurigheid. 
 
De beschreven onderzoeken zijn met raad en daad ondersteund door de medewerkers van 
onze afdeling, waarbij iedereen zich tomeloos wist in te zetten op de momenten dat dit 
nodig of gewenst was. Ruud, Dennis, Eka, Nico en Wesley hebben mij maar al te vaak 
bijgestaan in het lab. Onbewust hebben Carlien, Wouter en Annemariek mij, door hun 
enthousiasme in hun stages die ze bij mij voltooid hebben, een duwtje in de rug gegeven 
waardoor het doorgaan met werken aan de soms moeizame studies net dat stukje 
gemakkelijker ging. De andere medewerkers van de afdeling, waaronder Ingrid en Eline, 
zijn een bijzondere groep die soms onzichtbare, soms zichtbare steun bieden en altijd 
klaarstaan om te helpen. 
 
Ploeggenoten van de LUMC-8, een bonte verzameling over alle medische disciplines, 
hebben door hun interesse voor mijn onderzoek en hun suggesties voor de ideeën die wij 
graag tot uitvoer wilden brengen in ons onderzoek aangetoond dat het loont om in hetzelfde 
schuitje te zitten, en te roeien met de riemen die je aangeboden krijgt. Het feit dat ons 
boegballetje altijd als eerste over de lijn kwam geeft aan dat de kracht van het LUMC in de 
samenwerking te vinden is. Ploeggenoten uit mijn Oude Vier, waarvan ik de laatste ben die 
aan de verdediging van mijn proefschrift zal beginnen hebben mij vaak uit de wind 
gehouden, letterlijk op de fiets, figuurlijk door het relativeringsvermogen en goede 
voorbeeld. Klok, hoewel ik op de fiets vaak mijn voorwiel voor het jouwe weet te houden 
heb jij mij eruit gedemarreerd in de race om de promotie, een mooie motivatie om de 
achtervolging in te zetten! 
 
Broertje, zusjes, Arnold, Laura en Marjolein, jullie hete adem in mijn nek voor wat betreft 
het afstuderen en promoveren heeft mij vooruit geduwd wanneer dat nodig was. Het lijkt 
nog wel gisteren dat wij nog allemaal -op de juiste volgorde- op de achterbank bij pap en 
mam zaten, maar inmiddels zijn we allemaal al een stuk ouder en verder in het leven. Het is 
fijn om te weten dat er altijd mensen zijn om op terug te vallen, voor moeilijke en 
makkelijke gesprekken. 
Pap en mam, ik kan niet eens beginnen met uitleggen hoeveel jullie mij hebben geholpen in 
mijn werk en thuis. Ik ben heel blij dat jullie straks achter mij in de zaal zitten en weet dat 
het goed is. Bedankt!  
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Tessa, jouw begrip en mentale steun zijn onmisbaar geweest. De bergen die ik ben 
tegengekomen in het traject naar de verdediging zijn makkelijker te beklimmen geweest 
samen met jou. Ik kijk uit naar de plannen die wij nog voor ogen hebben. Het verbouwen 
aan ons eigen huis bevalt zo goed dat ik uitkijk naar meer gezellige, soms onbegrijpelijke 
en vaak hilarische momenten. 
 
Naast de mensen die hier genoemd zijn, zijn nog vele anderen, die ik niet bij naam 
genoemd heb betrokken geweest bij de totstandkoming van dit proefschrift en ook hen 
bedank ik hartelijk. 
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